Spot on Biotechnology Business 2016/2017 · Spot on Biotechnology Business 2016/2017 e ny e de....

BIO.NRWMerowingerplatz 1 40225 Düsseldorf, GermanyFon +49 211 385469-9200Fax +49 211 [email protected]

Ministry of Innovation, Science and Research of the German State of North Rhine-Westphalia 40221 Düsseldorf www.innovation.nrw.de

ww

w.b

io.n

rw.d

e

Company

Directory

Spot on Biotechnology Business 2016/2017

Online

Company

Database

www.bio.nrw.de

Online

Company

Database

www.bio.nrw.de

From Mind to Market: Biotechnology Company Directory 2016/2017

North Rhine-Westphalia

4

BIO.NRW

5

BIO.NRW

Editorial

innovation-friendly climate and infrastruc-ture which will assist the faster translation of knowledge and expertise into marketable products and techniques. This is done with a view to keep the regional biotech sector at the leading edge of technology and market savvy.

One of the keys to success is the coopera-tion across disciplinary lines. This booklet

Dear Reader,

North Rhine-Westphalia is the home of biotechnology. From the establishment of the Institute of Biotechnology at the Jülich Research Centre in the late 1970s to this day, the sector has been developing continuously. Our state has become a true biotech hub. Over the past nine years, the number of bio-technology firms in NRW has all but doubled - and this is looking only at those businesses that meet the OECD’s definition of ‘dedicated biotech firms’. There are more - and mostly bigger - companies where biotech products and processes account for a significant por-tion of the turnover. This creates jobs and helps retain the high quality of research and development.

Of course, our success did not spring from nowhere. In North Rhine-Westphalia, we have, on the one hand, all the right con-ditions, including an outstanding research landscape. On the other hand, biotechnol-ogy firms in our state are embedded in a robust environment of chemical and phar-maceutical global players. On top of that, the State Government is busily creating an

is intended to be a biotechnology almanac designed to help you make new contacts and find partners for cooperation.

Why not come to Cologne and use the opportunity to meet prospective partners face to face at the BIO-Europe 2016 event from 7 to 9 November. Visit the stand of the ‘BIO.NRW State Cluster’ at Europe’s premier business-to-business matchmak-ing conference for the life-science sector.

Let me now wish you successful networking and many new partners for cooperation.

Svenja Schulze

North Rhine-Westphalia Minister for Innovation, Science and Research

6

BIO.NRW

7

BIO.NRW

Greeting

mostly all modern industries, a big amount is still wasted, exemplary as not recyclable fuel material for energy production. More sophisticated technologies as well as more measureable parameters on the impact of bioeconomy on society and industry will become key elements for continuous suc-cess of bioeconomy.

To obtain more measurable data of the development of the biotech industry all Ger-man biotech clusters/regions agreed this year for the very first time on a consistent company/business survey conducted by BIO Deutschland e.V. These data will pro-vide deeper insides about the development of Biotech regions all over Germany. Making a long story short, the first report indicates a big success of the biotech companies in NRW, exemplary with an overall increase in turnover, money spend into Research & Development and increasing numbers of employees. A more illustrated analysis about the key developmental facts of this region is provided in the 8th annual compen-

Dear Reader,

Welcome to one of the world’s biggest biotechnology hotspots. The area of North Rhine-Westphalia (NRW) is one of Europe’s fastest growing biotech landscapes. With 95 dedicated biotechnology companies and 19 other life science related companies this is one of Germany’s densest biotech-networks, complemented with an excellent academic environment. Strikingly, also numerous global players are among these companies. Em-phasizing the importance of NRW’s biotech landscape, the biggest industrial deal of the year, the biggest deal a German company ever made, is currently being tied up here. The Bayer AG is buying the U.S. seed giant Monsanto for $66 billion, an event with global influence. The fusion of both companies makes Bayer the world’s largest supplier of agricultural chemistry. Obviously, biotechnol-ogy is tightly linked to this branch. The rising influence of biotechnology on our daily life reveals that it is one of the key technologies for the future development of our society and industry. Hence, it is not surprising that biotechnology was and is still shaping NRWs industrial landscape.

10 Years ago a key communiqué, the Cologne paper, was published, describing the societal challenges of a sustainable development by bioeconomy. The aim of bioeconomy is a circular economy, reducing pollution and direct processing of all pro-duced products incl. potentially unwanted waste products. More than 40 countries are by now actively promoting bioeconomy. Main ideas of a circular economy are al-ready accomplished, though there is still a long way to go. Biomass is not used in an optimal way, yet. Although, biomass supply chain management became a key feature of

dium of NRW’s biotech business landscape “Spot on Biotech Business”.

In March 2016 BIO.NRW hosted in part-nership with EIT Health the 5th Business Angel Congress in Dusseldorf. Here, more than 100 policymakers, business angel investors and government representa-tives came together, stimulating the en-trepreneurship and innovation for SMEs. BIO.NRW also became host of the Bio-Europe, Europe’s biggest partnering event in life sciences, taking place in Cologne in November 2016, adequately to the spatial origin and 10th birthday of the Cologne pa-per on bioeconomy. On the occasion of this event also the current issue of the “Spot on Biotech Business” is released. I invite eve-rybody to take advantage of our offerings and to engage with our state’s extensive and excellent biotech community.

Dr. Bernward GarthoffCluster BIO.NRW

Representative for Biotechnology of the German State of North Rhine-Westphalia

8

BIO.NRW

© 2016/17, BIO.NRW “Spot on Biotechnology Business” www.bio.nrw.de

Print: Druckstudio Gruppe, DüsseldorfDesign and Layout: it’s FR!TZ

Picture Source: p. 4 © SergiyN – fotolia.comp. 6 © it’s FR!TZ p. 10 © Chepko Danil – istockphoto.comp. 12 © Wavebreakmedia – istockphoto.comp. 14 © Li Ding – istockphoto.comp. 16 © anyaivanova – istockphoto.comp. 18 © Songsak Paname – istockphoto.comp. 20 © Shironosov – istockphoto.comp. 22 © anyaivanova – istockphoto.comp. 28 © Alex Raths – istockphoto.comp. 37 © BIO.NRW; Institute of Biochemistry, University of Colognep. 38 © Shironosov – istockphoto.comp. 52 © miszaqq – istockphoto.comp. 58 © Toa55 – istockphoto.comp. 61 © it’s FR!TZ p. 62 © HYWARDS – istockphoto.comp. 64 © luchschen – istockphoto.comp. 74 © G. Mönks – fotolia.com

9

BIO.NRW

Content

Editorial ……………………………………………………………………………… 5

Greeting ……………………………………………………………………………… 7

Spot on Biotechnology Business ………………………………… 11

Biotech Landscape …………………………………………………………… 11

Stimuli for Start-Up‘s ……………………………………………………… 11

Academic Biotech Research ……………………………………… 13

Biotech Business …………………………………………………………… 17

Competence Clusters …………………………………………………… 21

Industrial Biotechnology – CLIB2021 …………………………… 21

Pharmaceutical Biotechnology – BIO.NRW.red …… 23

From Mind to Market …………………………………………………… 23

Biotechnology Map of North Rhine-WestphaliaLife Science Technology Parks and Incubators …… 24

Biotechnology Map of North Rhine-WestphaliaDedicated and other biotechnologically active companies ……………………………………………………………………… 26

Company Directory 2015/2016 NRW

Non-specific Services …………………………………………………… 28

Health and Medicine (including Animal Health) …… 38

Industrial Biotechnology ……………………………………………… 52

Agrobiotechnology ………………………………………………………… 58

Bioinformatics ………………………………………………………………… 62

Other Biotechnologically Active Companies …………… 64

BIO.NRW Cluster Biotechnology North Rhine-Westphalia ……………………………………………… 70

Glossary …………………………………………………………………………… 72

OECD Definition ……………………………………………………………… 72

Organisation for Economic Co-operation and Development (OECD) …………………………………………………… 72

Biotechnology company ……………………………………………… 72

Dedicated biotechnology companies ……………………… 72

Other biotechnologically active companies …………… 72

Business Areas of Activity …………………………………………… 72

Contact BIO.NRW …………………………………………………………… 72

Sources, Literature, Links …………………………………………… 72

10

BIO.NRW

11

BIO.NRW

Spot on Biotechnology Business

Biotech Landscape

North Rhine-Westphalia (NRW) is at the heart of Europe. 150 million people – a third of the population of the European Union – live within a day’s drive of Düsseldorf, the state capital. 30 percent (i.e. EUR 189.8 billion in 2014) of the direct foreign investment that flows into Germany ends up in North Rhine-Westphalia, where some 18.000 international companies control their German and European op-erations from. NRW also is the number one trading state among Germany’s 16 federal states.1 Summing up the in- and export of NRW the trading volume is EUR 388.8 billion. With around EUR 646 billion, NRW generates 21.3 % of the German GDP, putting it clearly at the top of all German federal states. It ac-counts for 4.4 percent of the European GDP (EU-28), making it one of the most important economic regions in Europe. Comparing NRW in an international ranking, it is ahead of sev-eral European countries such as Switzerland, Sweden, Poland, Turkey and Belgium.2 With 17.9 million inhabitants of which 9.9 million live in the Rhine-Ruhr area, that lists among the top 35 metropolitan areas in the world – NRW is by far the most populous German state. Consequently, the state boasts the highest level of infrastructure within Ger-many including the country’s densest railway network and seven international airports. Handling more than 129 million tons of goods per year, Duisburg is the world’s largest inland port. With over 100 annual international trade fairs NRW has the largest trade fair venue of the world. Colognes “Koelnmesse” is the No.1 venue for more than 25 different industries. Traditionally, North Rhine-Westphalia has been Germany’s most important location for

the pharmaceutical and chemical industry. Today the state has also developed into a life sciences hotspot: A good reason for many top-level biotechnology companies and re-search institutes to have their headquarters here. Numerous successful start-up and spin-off companies are flourishing in NRW alongside a strong chemical and pharmaceu-tical industry that includes many well-known household names like Bayer, Evonik, Henkel, Grünenthal, Johnson & Johnson or UCB. This business excellence is endorsed by a dense network of outstanding academic institu-tions, which focus on biotechnology within a broad life sciences landscape. In addition, there is an equally rich and robust funding environment to support and promote the industry, including venture capital providers and business development organizations.

Biotechnology in NRW represents an active, multi-centric network, which is setting the

pace for the powerful pulse of the state’s life science business. Meanwhile biotechnology is a maturing industry that expands rapidly. Its innovative technologies are applied to major industry branches serving health/medicine, chemistry, food and environment. North Rhine-Westphalia has been developing its biotechnology hotspot since 1995. More than 20 years into the program, over 400 life science related companies are located here – among them 114 biotechnology enterprises including several global players (Figure 1). Major business areas covered are industrial, nano- and pharmaceutical biotechnology, and there is a focus on enabling technologies and supporting services as well. Combining the strong technical expertise evolving from these areas has been the key driver for NRW as the state is pioneering the field of bio-economy in Germany.

Stimuli for Start-Up‘s

Many of today’s successful young biotech companies started as university spin-offs. They took advantage of life science incuba-tors and technology centers, whose exist-ence can be pivotal for a start-up company. As catalysts for regional infrastructure and economic development, there are approxi-mately 60 such centers and incubators in the immediate vicinity of universities and basic research institutions in NRW. They support technology transfer all the way from mind to market. At the time of the editorial deadline of this brochure, a total of 158 biotech and life science related companies were incubated by 26 of these technology centers.3 You will find the respective locations of the centers and the number of biotech companies each

Fig. 1: Life Science Company Landscape in North Rhine-Westphalia

~329 other life science related companies

19 other biotechnologically active companies

95dedicated

biotechnologycompanies

12

BIO.NRW

13

BIO.NRW

of them hosts on the map on page 24. The services these start-up centers provide in-clude renting affordable laboratory and office space, mediating business contacts, consult-ing on funding opportunities, and advising on either founding or relocating a firm. Business-plan competitions are offered as an additional chance for support. One technology park that deserves to find special mention here is BioCampus Cologne, one of the largest of its type in Germany. It houses more than 23,000 square meters of office and laboratory space, including state of the art S1- and S2 labs, and industrial production facilities on a site totaling more than 25 hectares. Company founders, young entrepreneurs and scien-tists all profit from NRW’s highly-networked biotechnology scene.

Academic Biotech Research North Rhine-Westphalia is offering Ger-many’s most comprehensive network of academic institutions consisting of inter-nationally renowned Universities and Uni-versities of Applied Sciences (71; 25 with life science activity), Max Planck Institutes (13; 6 with life science activity), Fraunhofer Institutes (14; 5 with life science activity), Helmholtz Institutes (3; 3 with life science activity) and Leibniz Institutes (11; 7 with life science activity). One quarter of all German students are taking advantage of this excellent environment for science and education and are pursuing their studies in NRW, remarkably one third of all STEM fields (Science, Technology, Engineering and Mathematics) students are studying in NRW. University centers can be found in Aachen, Bonn, Cologne, Düsseldorf, Mün-ster, Bochum, Essen, Dortmund, Bielefeld, and other cities in the state. In the area of biotechnology, specializations in cell biol-ogy, (bio-) medicine, biochemistry, genom-ics, proteomics, metabolomics, molecular biology, systems and synthetic biology,

analytics/microsystems, bioinformatics and process engineering are all on offer. For over a decade, NRW has been the lead-ing German region in stem cell research and development with Münster, Bonn and Cologne as hotspots. In the field of plant

genetics, the Max-Planck-Institute for Plant Breeding Research, Cologne deserves to be called the “cradle of plant biotechnology” in Germany as the first plant transformation technologies were developed here. It is now tightly interacting with the newly founded

Fig. 3: Growth of life science companies compared to dedicated biotech companies

Fig. 2: Biotechnology is a strongly linked industry

100

80

60

40

20

0

Life Science companies Biotech companiesaccu

mu

late

d p

erce

tage

of c

om

pan

ies

1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015

IDEA MARKET

Branch Product/Service

Agriculture (functionalized) Foods / Fertilizer / Crops / Plant Protection

Basic Research Basic/fundamental / Pre-requisite for applied reserach and development

(Biomedical) - IT Laboratory Information Systems / Digital Healthcare / Biological Computing / Databases

Chemical Industry Proteins / Peptides / Chemicals through BiotechProcesses (Enzymes, MO) / Molecular Electronics

Energy Raw Materials/ Fuels

Facilities / Infrastructure Transport ⁄ Laboratory supply / Materials

Healthcare / Pharma Drug Delivery / (Companion) Diagnostics /Medical Devices / Therapeutics

BIO

TE

CH

NO

LOG

Y

14

BIO.NRW

15

BIO.NRW

Cluster of Excellence on Plant Science (CEPLAS) that was founded in 2012 - an EUR 32 million collaboration of several universities and research institutes. Re-cent examples from Cologne emphasize the very dynamic development of NRW as a research location: in May 2013 the all new research facilities of CECAD (Cluster of Excellence – Cellular Stress Responses in Aging-Associated Diseases) have been opened – an investment of EUR 85 million. In October 2013 the Max-Planck Society

Fig. 4: Size of Dedicated Biotechnology Companies (Number of Employees)

Table 2: Number of dedicated biotech com-panies

Table 1: Key Figures for the Biotechnology Industry of North Rhine-Westphalia

95 dedicated biotechnology companies in 2015 (89 in 2014, 87 in 2013, 84 in 2012 )

2012 2013 2014 2015 2015

Number of employees* 3,758 (n=67) 3,680 (n=67) 3,758 (n=68 ) 3,983 (n=75) 4,387

Turnover* EUR 1.34 bn (n=32) EUR 1.27 bn (n=29) EUR 1.32 bn (n=25) EUR 1.51 bn (n=30) EUR 1.66 bn

R&D expenditure* EUR 190 m (n=30) EUR 214 m (n=29) EUR 241 m (n=22) EUR 258 m (n=30) EUR 337 m

based on survey BIOCOM based on survey BioDeutschland

based on survey Biodeutschland and imputation statistics

opened the new facility of the Max-Planck Institute (MPI) for Biology of Ageing in im-mediate vicinity to the new CECAD building on the university campus. They offer cutting edge infrastructure and technology, incl. laboratory and office space for together more than 700 international scientists, staff and students. Directly next to the MPI and CECAD the Cancer Center Cologne (CIO) is located. To obtain a fast pipeline from basic research to final therapeutics the CIO is cur-rently being expanded for EUR 78 million.

* Data based on survey data as indicated; n means number of companies giving indication

below 10 10-49 50-250 more than 250

Therapeutica Diagnostica Drug Delivery Industrial biotechnology Bioinformatics Agrobiotechnology Non-specific services

43%

10%7%

40%

Business Year NRW / %* Germany

2007 53 / 10.7 496

2008 61 / 12.2 501

2009 68 / 12.8 531

2010 71 / 13.2 538

2011 77 / 14.0 552

2012 84 / 14.9 565

2013 87 / 15.3 570

2014 89 / 15.4 579

2015 95 / 16.1 590* % of Germany total

25%

14%

27%

8% 5%

5% 11%

Fig. 5: Areas of activity

Here, newest research progress is directly implemented into individual therapies for the patient’s well-being.

Additionally several world leading neurosci-ence institutes are located in close proximity. Alone in 2013 more than EUR 193 million was invested into the neuroscience research facilities of the DZNE (German Center for Neurodegenerative Diseases) and the de-

16

BIO.NRW

17

BIO.NRW

partment of the university hospital Bonn. Along with the respective institutes of the Universities of Cologne and Bonn as well as their University Hospitals plus the DZNE in Bonn, Cologne has been developed into a world-wide unique competence center for ageing research. About one hour east of Co-logne, Europe’s most innovative technology campus is currently taking shape: covering 800.000 square meters, “Campus Melaten” of the RWTH Aachen University will house up to 11 technology clusters, among them the “cluster biomedical technology” and take up investments of EUR 1 billion. Coopera-tion of academia and industry are creating synergy effects, e.g. recently the Forschungs-zentrum Jülich initiated a cooperation with Bayer on plant root and shoot phenotyping. BIO.NRW offers detailed information about the academic life science landscape in NRW in its compendium “Spot on Biotechnology Science. This brochure is composed in a similar manner like „Spot on Biotechnol-ogy Business“ and presents a total of 227 profiles of research institutes, centers and facilities in NRW. Its second issue has been released simultaneously with this brochure in November 2016.

Biotech Business

Biotechnology became one of the most dy-namic business sectors over the last decades. Having such a complex industry it is hard to find a simple value chain or to separate it from other, more “static”, industries. Biotechnol-ogy routinely uses other technologies, e.g. Nanotechnology and Engineering, to improve products. However, all colors of biotechnol-ogy (green, red, white and blue) are linked to diverse other branches like the chemical industry (Figure 2). Looking on single services and products makes it obvious that looking on dedicated biotechnology companies only reveals a minority of the impact biotechnology has on the entire industry. A good example

Indication Number of Products

Neoplasms / cancer / oncology 32

Infectious and parasitic diseases 10

Diseases of the nervous system 7

Symptoms, signs abnormal clinical and laboratory findings, not elsewhere classified 6 Skin and subcutaneous tissue 4

Musculoskeletal system and connective tissue 3

Diseases of the blood and blood-forming organs; immune disorders 2

Respiratory 2

Mental and behavioural disorders 2

Other 2

Cardiovascular 1

Digestive system 1

Total 72

Fig. 6: Drug Development Pipeline by Indication

for this is the energy branch with respect to biofuel. The revenue of biofuel was alone in the U.S. $9.7 billion in 2012.4 In terms of the definition of a dedicated biotech company, the production of biofuel does not belong to the biotech industry, even though mostly all production process steps are based on biotech techniques. Obviously, more distinct definitions may help to analyze the impact of biotechnology on the overall industry and society.

To have a more uniform definition of biotech companies for Germany BIO Deutschland e.V., the branch association of the German biotech industry and organizations, decided to intro-duce a new statistical analysis, carried out by

BIO Deutschland itself. This statistical analy-sis will allow a more sophisticated analysis of the biotechnology landscape in Germany. It was carried out this year for the very first time and will be continued over the next decades, facilitating a more comprehensive compari-son for all individual German states over the next years. The framework of the analysis is set by the OECD definition of a dedicated biotech company and biotech associated companies (see page 72). Based on this defi-nition, 95 dedicated biotech companies were operating in NRW in 2015. Their activities were complemented by 19 other companies with a biotechnological commitment, mostly global players in the field of pharmaceuticals,

18

BIO.NRW

19

BIO.NRW

chemicals or seed production. Since these companies are active in many diverse areas, their biotech related business figures cannot be calculated exactly and are not included in the following statistics. The real economic impact of biotechnology in NRW is therefore higher than these statistics reveal. These companies are at the innovative core of biotechnological research and development. In contrast to the business figures of the dedicated biotech companies – as an exam-ple – the 2015 sales of Bayer AG and Evonik Industries AG alone, both headquartered in NRW, are EUR 46.3 billion and EUR 13.5 bil-lion, respectively. Even though only a part of their turnover can be assigned to NRW sites and not all products are generated involving biotech processes, the key business sectors of both companies are based on biotechnology. These two examples clearly demonstrate the enormous impact biotechnology has on the overall industry in NRW and Germany.

According to the 2009 OECD Biotechno-logical Statistics report (which – except for limited “indicator” updates - still is the latest published detailed study in the field by the OECD), North Rhine-Westphalia is Europe’s most innovative biotechnology region: It generates more biotech PCT patent applica-tions than any other European region.5 The development of biotech innovations from NRW has been constantly increasing: 4,121 biotech patents have been filed in total between 1996 and 2010 by NRW biotech companies and research facilities of which 4,118 have been published.6

The business figures of the 95 NRW dedi-cated biotech companies are set into com-parison with the 590 German dedicated companies and the 495 German companies without the NRW contribution, respectively. In NRW about 4,000 people (of about 18,000 nationwide) – more than in any other German federal state – were employed by dedicated biotech companies in 2015 and generated a turnover of approximately EUR 1.51 billion

Fig. 7: Drug Development Pipeline by Phase

(Table 1). According to the national company survey by Ernest & Young the NRW dedicated biotechnology companies generated about 44.4% of the German biotech annual turnover (EUR 3.4 billion expected) in this sector which is a slight increase compared to 2014.7 Thus, the biotech industry in NRW is - to a large ex-tend - responsible for the economic impact of the German biotech business as a whole. EUR 258 million – a significant annual increase by 7.1% compared to 2014 and 20.6% compared to 2013 (EUR 241 and EUR 214 million) – was reinvested into R&D projects.8 The develop-ment of this key business figure underlines that the investments by the dedicated biotech companies in NRW are persistent and will ad-vance the future market position of NRW bio-tech. Together, NRW biotech firms are placing the highest investments for R&D of innovative products – nationwide. Overall, the propor-tional expenditure for R&D of 17.1% of the an-nual turnover is more than 5 times higher than the mean of all other businesses in Germany (average of 2.9%).9 The figures reflect that biotechnology as a business sector is in the process of maturation: 46 % of all life science companies are older than 20 years and were founded before 1997 whereat only 24 % of all biotech companies in NRW already existed in 1996. Looking at the balance of still existing

and newly founded companies in average 10.1 successful life science companies were founded annularly (within an annual growth rate of 3.0 %). At the same time 4.6 successful biotech companies were established (growth of 4.2 %). Hence, 45.7 % of all new founded life science companies are in fact biotech companies (in 1996 17.6% of all life science companies were biotech companies, 27.4% in 2016) (Figure 3). However, important factors that reduce the average company age in the industry are new foundations and acquisitions of successful ventures by global players as well as re-orientations of companies. The employee structure remains almost unchanged: about 83 percent of the biotechnology companies in NRW employ fewer than 50 people and 93 percent of the companies have less than 100 employees (Figure 4). After financing rounds of EUR 58.9 million in 2014, mostly due to AYOXXA Biosystems GmbH (EUR 20.3 million) and Protagen AG (EUR 10 million), financing rounds of biotech companies dropped to EUR 24.7 million in 2015, mostly contributed by Neuway Pharma GmbH with EUR 5.9 million. With six new dedicated and three new other biotech-active companies in NRW in 2015 the state’s biotech scene continues to be one that’s growing at fastest pace in Germany. Over the past two years the state even counts

On the Market6

n/a 4

Lead optimization1

Preclinical47

Phase III3

Phase II2

Phase I8

Discovery7

20

BIO.NRW

21

BIO.NRW

12 new companies leading to 95 dedicated and 19 and other biotech active companies today (Table 2). In 2015 27 percent (32 in 2014) of the biotech companies in North Rhine-Westphalia were active in multiple branches (Figure 5). These biotechnology companies with “nonspecific business activities” include service providers and suppliers for the indus-try. Germany’s two largest biotech companies with the highest numbers of employees in Germany 10, QIAGEN GmbH and Miltenyi Biotec GmbH used to be listed here. As Qiagen has developed into the field of medi-cal applications, meanwhile the company is accounted as a dedicated biotech company in the „health-medicine“sector in this sur-vey. QIAGEN began as a spin-off from the University of Düsseldorf in 1984. Today, the company employs more than 4,600 experts at 37 sites worldwide, and has become the leading provider of sample technology and a top player in molecular diagnostics especially in cancer detection and prevention. Through a number of strategic moves QIAGEN today is one of the leading companies in biomarker discovery and development (i.e. companion diagnostics), which is the basis for the com-pany’s redirection to the health business. Based on the invention of a magnetic cell separation technology, Miltenyi Biotec was founded 1989 in Bergisch Gladbach near Cologne. Since then, the company has ex-panded to 1,600 employees worldwide who produce and market over 11,000 products for the global biomedical research community. It is remarkable that this success has been solely achieved by generic growth. The ma-jority of dedicated NRW biotech companies (46%; 44.9% in 2014) are active in the field of health and medicine developing new drugs or diagnostics within the pharmaceutical sector. At the time of the editorial deadline of this brochure the dedicated biotech companies in the field of health and medicine had devel-oped a drug pipeline of in total 72 products and product candidates, remaining mostly

constant over the last years. The detailed distribution by indication lists as clear top one category “neoplasms/cancer/oncol-ogy”, it increased by 15 compared (2015 - 17 products) to 32 products in pipeline in 2016 (Figure 6). This is followed by “infectious and parasitic diseases” that dropped from 18 (2015) to 10 products in pipeline (2016). “Dis-eases of the nervous system” (7) remained mostly constant compared to 2015 with 9, and “symptoms, signs and abnormal clinical and laboratory findings” (6) increased by 5 (1 product in 2015). The pipeline includes 13 therapeutics (18.1%) in the clinical phases I to III (17 in 2015, Figure 7).11 The majority of products (47 – 65.3%) are preclinical drug candidates. The overall number of products in development pipeline slightly dropped compared to 2015 with 78 products (-6.7%).

With 14 percent (16.9% in 2014) – com-pared to 10.1 percent of companies in this sector across Germany – industrial biotech-nology remains a characteristic strength of NRW.12 The underlying classification refers to companies that develop enzymes, biomateri-als or bioprocesses, which can be applied to facilitate or enable large-scale production in the chemical industry. The NRW-based companies Henkel and Evonik have been pio-neering industrial biotechnology worldwide and are still its pacesetters.

Competence Clusters

Besides the large number of biotech com-panies, which have specialized in enabling technologies, two main fields of activity characterize the biotechnology landscape in North Rhine-Westphalia: Industrial Biotech-nology and Pharmaceutical Biotechnology.

Industrial Biotechnology – CLIB2021

CLIB2021 (Cluster Industrial Biotechnology 2021) is an international open innovation cluster of large companies, SMEs, academic

institutes and universities as well as other stakeholders active in biotechnology and bioeconomy as a whole. The cluster com-prises over 100 members with a share of about 25 % international members. The overall goal of CLIB2021 is to network stake-holders along and across value chains and to identify new opportunities for innovation, projects, and business. The cluster mainly focuses on industrial biotechnology to pro-vide solutions for the chemical industry: raw materials, biocatalysts, processes, products and technologies that result in monomers, fine chemicals or in their functionalization. Pertinent project areas are identified by the CLIB2021 team in conjunction with members in an iterative process. CLIB2021 is a non-profit association, with its members shaping the cluster’s interests and activities. The cluster coordinates several associated programmes which cover different aspects of bioeconomy, and invites members to become involved, bring in their own ideas and to generate a real benefit for their companies or institutions. To this end, CLIB2021 organizes a number of events throughout the year: the annual CLIB international conference (CIC), forum events, topic-specific workshops, dedicated small partnering meetings and visits to partners, sites or meetings in Germany and abroad.

In NRW, CLIB2021 is coordinating the regional innovation network (RIN) “Stoffströme”, which seeks to improve exploitation of bio-mass, wastes and side streams in the region. This action is funded by NRWs Ministry of Innovation, Science and Research (MIWF). Another NRW-based project is dedicated to improve identification and production of high performance ingredients (HiPerIn) for markets like adhesives, cosmetics or food and feed. Together with partners in Germany, Flanders and the Netherlands, CLIB2021 is currently establishing the BioInnovation Growth mega-Cluster (BIG-C). This is sup-ported by the German Federal Ministry of Education and Research (BMBF) through a

22

BIO.NRW

23

BIO.NRW

5-year, 4 million Euro project, that started in 2016. It deals with the development of cross-border novel value chains based on lignocellulose and the C1 gases CO and CO2 to produce chemicals. Moreover, it focuses on cross-border education concepts conveying required competences for the establishment of a circular economy.

Pharmaceutical Biotechnology – BIO.NRW.red

In the last decades, major milestones in medicine and healthcare have been achieved through pharmaceutical (“red”) biotechnol-ogy, namely in the development of drugs, vac-cines and diagnostics. In 2015, half of all 590 dedicated German biotech companies (51%) belong to the red biotechnology field. Two-third of this sector belong to the therapeutics segment, focused on drug development.12

With a closer look to the medical bio-technology area, respectively to biophar-maceuticals it becomes obvious that 2015 was another strong year. 15 out of 50 newly approved drugs were biopharmaceuticals, more than ever before (30%). 13 Their sales in Germany increased by 9.7% in 2015 rela-tive to 2014 and reached a volume of about EUR 8.2 billion, which corresponds to 22.9% of the total pharmaceutical market in 2015. Indications with a high medical need are still immunological diseases and Oncology and the increase in growth was most significant in these segments (Immunology by 11% and Oncology by 12%). It is interesting to note that more than two-third (71%) of the biopharma-ceutical sales is generated by indications in immunology, oncology and metabolism.13

For more than a century, NRW has been the heartland of Germany’s pharmaceutical industry and has an exceptional standard in biotechnological and medical education. This advantage, combined with the enormous market potential of biopharmaceuticals, gave reason for BIO.NRW’s strategic initiative in

the field of red biotechnology called BIO.NRW.red. Its starting point was the competi-tion “Bio.NRW” in 2009, a call for projects announced by NRW’s Ministry of Innovation, Science and Research (MIWF) to support the formation of consortia between academia and biotech companies. The focal areas of the successful projects were: development of drugs (biologicals and small molecules), generation of new methods in diagnostics, establishment of biomarkers and introduc-tion of new biopharmaceutical technology platforms – especially based on cell cultures technology.

Since 2009 the MIWF announced several further calls for proposals in the field of red biotechnology like “PerMed.NRW” (by the end of 2010), focused on personalised medi-cine and “Translational Stem Cell Research” (finished in June 2014). These activities continue to effectively boost the BIO.NRW.red initiative.

By the end of 2014 a new series of competi-tions were published by NRW’s state govern-ment, focussing on translational research in eight so-called “main markets” (NRW Leit-marktwettbewerbe), adopting a “two-rounds funding model”. The results of the first round in the main market “Life Sciences” were published in December 2015. Ten innovative research projects will be funded by 20 Million euros.14 The announcement of the results for the second round (ended in June 2016) will be expected in the end of October 2016. Members of the new successful consortia will expand the sustainable BIO.NRW.red network that connects major contributors to medicine, healthcare, the pharmaceutical industry and red biotechnology in the state.

From Mind to Market

This chapter provides an overview of 81 of the dedicated and 12 of the other biotech-nological-active companies from North Rhine-Westphalia as classified following the

OECD guidelines (page 72). For convenience, the companies are grouped in five areas ac-cording to their main business:

Non-specific Services Health and Medicine

(including Animal Health) Industrial Biotechnology Agri/Agrobiotechnology Bioinformatics Other biotechnologically companies

For a more comprehensive directory that in-cludes all life science and life science related companies in NRW, please visit our company database at www.bio.nrw.de/en/company_da-tabase.

BIO.NRW invites you to discover North Rhine-Westphalia‘s biotechnology com-munity!

24

BIO.NRW

Q

Bonn

Q Witten

Q Gronau

Q Hilden

Q

Essen

Q Langenfeld

Q Troisdorf

Q Rheda-Wiedenbrueck

Q Nettetal

Rhine

Rhine

Ruhr

The Netherlands

Belgium Germany

Lippe

Ems

Weser

Q Wuppertal

4

Q Bielefeld

Q Bergisch-Gladbach

Q MünsterQ Ascheberg

3

2

10

3

3

3

6

7

610

4

22

14

8

27

Q Aachen

1

DortmundQ

4

Q Köln5

3

Q Kempen

Q JülichBaesweiler

Q

Düsseldorf Q

Q Bönen2

1

Bochum Q

Essen

Q

Biotechnology Map of North Rhine-WestphaliaLife Science Technology Parks and Incubators

Herzogenrath Q

Rheinbach Q

5 3Q

Witten

Q Monheim

1

25

BIO.NRW

Name City Companies* Homepage

1 Zentrum für Bio-Medizintechnik (ZBMT) Aachen 4 www.agit.de

2 INCA Technologiezentrum GmbH Ascheberg 3 www.inca-technologiezentrum.de

3 its-Internationales Technologie- und Service-Center Baesweiler Baesweiler 7 www.its-center.de

4 Technologiepark Bergisch-Gladbach Bergisch-Gladbach 4 www.tbg.de

5 Technologiezentrum Bielefeld Bielefeld 3 www.technologiezentrum-bielefeld.de

6 BMZ - BioMedizinZentrum Bochum Bochum 6 www.bmz-bochum.de

7 TZR - Technologiezentrum Ruhr Bochum 2 www.chip-tzr.de

8 Bio-Security Bönen 10 www.bio-security.de

9 B1st Software-Factory Dortmund Dortmund 1 www.b-1st.de

10 BMZ - BioMedizinZentrum Dortmund Dortmund 27 www.bmz-do.de

11 Zentrum für Mikro- und Nanotechnologie Dortmund 1 www.mst-factory.de

12 LSC - Life Science Center Düsseldorf Düsseldorf 14 www.lsc-dus.de

13 ETEC - Essener Technologie- und Entwicklungs-Centrum GmbH Essen 1 www.etec.de

14 TPH - Technologie Park Herzogenrath Herzogenrath 6 www.tph.de

15 Technologiezentrum Jülich Jülich 2 www.tz-juelich.de

16 TZN - Technologie- und Gründerzentrum Niederrhein GmbH Kempen 3 wwwtzniederrhein.de

17 BioCampus Cologne Grundbesitz GmbH & Co. KG Köln 22 www.biocampuscologne.de

18 RTZ - Rechtsrheinisches Technologie- und Gründerzentrum Köln Köln 3 www.rtz.de

19 TechnologiePark Köln Köln 5 www.tpk.de

20 Creative Campus Monheim Monheim 10 www.cc-monheim.de

21 Technologieförderung Münster GmbH Münster 8 www.technologiefoerderung-muenster.de

22 CeNTech - Center for Nanotechnology Münster 4 www.centech.de

23 Gründer- und Technologiezentrum Rheinbach Rheinbach 3 www.wfeg-rheinbach.de

24 Forschungs- und Entwicklungs-Zentrum Witten GmbH Witten 5 www.fez.de

25 ZBZ - Zahnmedizinisch Biowissenschaftliches Forschungs- und Entwicklungszentrum Witten GmbH Witten 3 www.zbz-witten.de

26 Technologiezentrum Wuppertal W-tec GmbH Wuppertal 1 www.w-tec.de

Total: 26 158

* Life Science Companies

26

BIO.NRW

Rhine

Rhine

Ruhr

The Netherlands

Belgium Germany

Lippe

Ems

Weser

Q Bielefeld

Q

Bonn

Q

Nettetal

Q Witten

Q Gronau

Q

Bochum

Gelsenkirchen Q

Q HildenDüsseldorf Q

Moers Q

Q Marl

Q Bergisch Gladbach

Q Leopoldshöhe

Q Bad Salzuflen

Q TroisdorfQ St. Augustin

Q Aachen

Q Rheda-Wiedenbrück

Q JülichBaesweilerQ

Q Erkrath

MünsterQ

Q Köln

Q Wuppertal

Q

Osnabrück

Niederkassel Q

Biotechnology Map of North Rhine-WestphaliaDedicated and other biotechnologically active companies

Q Dortmund

Q LeverkusenQ Langenfeld

Q Ascheberg

Q

Essen

BergkamenQ

Mönchengladbach QMonheim Q

Neuss Q

Q Bottrop

Duisburg Q

Mechernich Q

Q Würselen

QHerzogenrath

Q Bönen

Q Westerkappeln

27

BIO.NRW

1 List of dedicated biotechnology companies in the fiscal year 2015 1 2 OECD Definition page 72 3 including company sites in NRW that are not headquarters and are therefore not accounted as NRW-based companies in the annual study by “BIO Deutschland e.V.”

Dedicated companies1, 3

A2M Pharma GmbH Monheim p. 39Adhesys Medical GmbH Aachen p. 39Affectis Pharmaceuticals AG Dortmund p. 39AgroProtect GmbH Aachen p. 59AiCuris GmbH & Co. KG Wuppertal p. 40Algiax Pharmaceuticals GmbH Erkrath p. 40arrows biomedical Deutschland GmbH Münster p. 40ARTES Biotechnology GmbH Langenfeld p. 29Autodisplay Biotech GmbH Düsseldorf p. 53Axiogenesis AG Köln p. 41AYOXXA Biosystems GmbH Köln p. 29Baliopharm GmbH Jülich p. 41BBT Biotech GmbH Baesweiler p. 29BIBITEC Gesellschaft für Prozessentwicklung mbH Bielefeld p. 30BioCheck GmbH Münster p. 41Biofrontera AG Leverkusen p. 42BioPIT Mining Company GmbH Münster BioSolveIT GmbH Sankt Augustin bitop AG Witten p. 53BSV Bioscience GmbH Baesweiler p. 53Carpegen GmbH Münster p. 42CellAct Pharma GmbH Dortmund p. 42CellSystems Biotechnologie Vertrieb GmbH Troisdorf p. 30Cevec Pharmaceuticals GmbH Köln p. 43Charles River Biopharmaceutical Services GmbH Erkrath p. 30ChemBiotech Münster Chimera Biotec GmbH Dortmund p. 31CIBUS Biotech GmbH Rheda-Wiedenbrück p. 31Cilian AG Münster p. 43CIRES cell & immune research services Dortmund p. 43Colbourne Pharmaceuticals GmbH Niederkassel p. 44Cube Biotech GmbH Monheim p. 31Cysal GmbH Münster p. 54Deutsche Saatveredelung GmbH Mechernich p. 59DIREVO Industrial Biotechnology GmbH Köln p. 54Epivios GmbH Düsseldorf evoxx technologies GmbH Monheim p. 54GEN-IAL GmbH Troisdorf p. 55IIT an der Universität Bielefeld GmbH Bielefeld p. 63IMAX Discovery GmbH Dortmund p. 55IMD Natural Solutions GmbH Dortmund p. 55InBio GbR Duisburg InfanDx AG Köln p. 44Informium AG Bergisch GladbachIsoloid GmbH DüsseldorfLead Discovery Center GmbH Dortmund p. 44Life & Brain GmbH Bonn p. 45Lonza Cologne GmbH Köln p. 32m2p-labs GmbH Baesweiler/Aachen p. 56Matricel GmbH Herzogenrath p. 45MetaVi Labs GmbH Witten p. 45miacom diagnostics GmbH Düsseldorf p. 46MILTENYI BIOTEC GmbH Bergisch Gladbach p. 32MLM Medical Labs GmbH Mönchengladbach p. 46Molekular Biologisches & Biochemisches Labor Dr. Bartling GmbH BielefeldMorphoplant GmbH Bochum p. 46

multiBIND biotec GmbH Köln p. 56MykoMax GmbH Wuppertal p. 59NEO New Oncology AG Köln p. 47NeraCare GmbH BönenNEUWAY Pharma GmbH Bonn p. 47Nexigen GmbH Köln p. 47PAIA Biotech GmbH Köln p. 32PAION AG Aachen p. 48Pharmedartis GmbH Aachen p. 48Phytowelt GreenTechnologies GmbH Nettetal p. 60PL BioScience GmbH Aachen p. 33PlasmidFactory GmbH & Co. KG Bielefeld p. 33Protagen AG Dortmund p. 48Protagen Protein Services Dortmund p. 33Protectimmun GmbH Gelsenkirchen p. 49PS Biotech GmbH Aachen p. 34QIAGEN GmbH Hilden p. 49QLAYM Healthcare AG DüsseldorfRidom GmbH Münster p. 63Rigontec GmbH Bonn Saaten-Union BIOTEC GmbH Leopoldshöhe p. 60SanguiBioTech GmbH Witten p. 49Senzyme GmbH Troisdorf p. 56SeSaM-Biotech GmbH Aachen p. 57Sibion Biosciences GmbH Bonn SIT Soft Intelligent Therapeutics GmbH & Co KG Dortmund p. 50Sividon Diagnostics GmbH Köln p. 50Soluventis GmbH Bochum p. 50Squarix GmbH Marl p. 34Syntab Therapeutics GmbH Aachen p. 51Sysmex Partec GmbH Münster p. 34TaconicBiosciences GmbH Köln p. 35Transimmune AG Düsseldorf p. 51vivo Science GmbH Gronau p. 35W42 Industrial Biotechnology GmbH Marl p. 57WeissBioTech GmbH Ascheberg XanTec bioanalytics GmbH Düsseldorf p. 35Xell AG Bielefeld p. 36

Other biotechnologically active companies2, 3

Bayer AG Leverkusen p. 65Cellex Gesellschaft für Zellgewinnung mbH Evonik Degussa GmbH EssenEvonik Industries AG Essen p. 65German Seed Alliance GmbH Köln p. 65Grünenthal GmbH Aachen p. 66Henkel AG & Co. KGaA Düsseldorf p. 66Janssen-Cilag GmbH Neuss p. 66Labopharm GmbH BönenMEDIWISS Analytik GmbH Moers Monsanto Agrar Deutschland GmbH Düsseldorf p. 67Octapharma GmbH Langenfeld Pharma Waldhof GmbH Düsseldorf p. 67Syngenta Seeds GmbH Bad Salzuflen p. 67Taros Chemicals GmbH & Co. KG Dortmund p. 68UCB GmbH Monheim p. 68W. von Borries-Eckendorf GmbH & Co. KG Leopoldshöhe p. 68

28

Non-specific Services

29

BIO.NRW non-specific services

Name

Address Postal Code/City

FonFax

E-MailInternet

EmployeesFounded (year)

ARTES Biotechnology GmbH

Elisabeth-Selbert-Str. 940764 Langenfeld

+49 2173 27587-0+49 2173 [email protected] www.artes-biotechnology.com22 2002

ARTES Biotechnology is an independent technology provider for the pharmaceuti-cal industry. Our business focus is on: • vaccine development (VLP technology) • process development of biopharma-

ceuticals• transfer of biosimilar processes

Our technologies have resulted in innova-tive products marketed worldwide. WHO

recommendation, international registra-tion, EMA resp. FDA approval and GRAS certification are achieved in international collaborations. Expression platforms in-clude high yield yeasts and E. coli system for efficient protein production. Our unique chimeric virus like particle (VLP) platform METAVAX® is best suited for the develop-ment of highly immunogenic vaccines in human and animal health.

Our proprietary technologies ensure freedom-to-operate and reliable, competi-tive production of innovative targets mar-keted worldwide.

BBT Biotech GmbH

Arnold-Sommerfeld-Ring 2852499 Baesweiler

+49 2401 93310-0+49 2401 [email protected]

301999

Name


FonFax

E-Mail Internet


BBT Biotech GmbH produces freeze-dried viable bacteria (probiotics like lactobacilli, bifidobacteria, yeasts) and metabolites not only in bulk but also in finished dosage forms to the pharmaceutical and health-food industriy.

The fermenter capacity is up to 18.000 l. The downstream process is based on sepa-

rators, filtration systems, chromatography and freeze dryers. On the basis of individual needs BBT Biotech GmbH also offers active pharmaceutical ingredients like thrombo-lytics (streptokinase, urokinase), fertility hormones (HCG, HMG, FSH), inhibitors (Aprotinin, UTI) and others (Hyaluronidase, Corticotrophin).

AYOXXA Biosystems GmbH

Nattermannallee 150829 Köln

+49 221 222529-0+49 221 222529-11 [email protected]

352010

Name


FonFax

E-Mail Internet


AYOXXA Biosystems GmbH is an interna-tional biotech company based in Cologne (Germany) with offices in Boston (USA) and Singapore. LUNARIS™ is AYOXXA’s innova-tive, patented beads-on-a-chip technology platform to analyze picogram amounts of multiple biomarkers in biological samples.It delivers a high-quality immunoassay

for sample volumes down to single-digit microliter, greatly expanding the types and number of samples from which scientists can gain insights. AYOXXA opens protein multiplexing opportunities to biomedicine, all the way from basic research to clinic and translational discoveries covering oph-thalmology, mouse-to-man and immuno-oncology applications.AYOXXA offers a selection of Multiplex detection kits, Control & Analysis Software. With the introduction of the AYOXXA Reader AR01, the company now provides a fully integrated solution for LUNARIS™ multiprotein analysis.

30

BIO.NRWnon-specific services

Name


FonFax

E-Mail Internet


Name


FonFax

Internet


BIBITEC GmbH

Universitätsstr. 2533615 Bielefeld

+49 521 106-6326 +49 521 106-156233 www.bibitec.de

102001

Name


FonFax

E-Mail Internet

Founded (year)

CellSystems Biotechnologie Vertrieb GmbH

Langeler Ring 553842 Troisdorf

+49 2241 25515-0 +49 2241 25515-30 [email protected] 1992

Since its formation CellSystems® has been a reliable partner for the life science community. CellSystems offers highly so-phisticated research products, including EU validated 3D in vitro skin models for research and toxicology assays that were developed and are produced at our onsite laboratories. Additionally, CellSystems offers a wide range of contract services.

In 2010, we opened our new clean room laboratories to meet the growing demands for various 3D tissue models and services. Today, our portfolio comprises a wide range of products for cell biology research and in vitro toxicology studies.

CellSystems is certified ISO 9001:2008.

BIBITEC Gesellschaft für Prozessentwick-lung mbH is specialized in the production and purification of proteins (e.g. hor-mones, mAbs) derived from mammalian cell cultures.

One major achievement was an eryth-ropoietin (EPO) project that involved the process development and the GMP-compliant production of an EPO biosimilar for use in phase III clinical trials.

The entire production and purification process was successfully transferred for large-scale production leading to one of the first successful approvals of a biosimi-lar in Europe.

In 2012 BIBITEC became part of Nord-mark Arzneimittel GmbH & Co. KG, Uetersen. In cooperation with Nordmark and other validated partners BIBITEC pro-vides all activities from “gene to product” including cell line and process develop-ment, GMP production, fill-and-finish and analytics.

Charles River Biopharmaceutical Services GmbH

Max-Planck-Str. 15a40699 Erkrath

+49 211 9255-300+49 211 [email protected]

Charles River Biopharmaceutical Services GmbH is a leading contract service organi-zation providing innovative and tailor-made solutions for the quality control of biophar-maceuticals.

We operate in full compliance with the GMP/GLP standards. Our testing facilities in Erkrath and Köln, Germany are part of a

global scientific network offering services that span the entire drug development process. This allows us to provide our clients with more flexibility, experience and expertise to maximize resources and optimize results based on their specific program needs.

Our services include: cell bank testing; analysis and clearance validation of con-taminants and impurities (residual DNA, host cell proteins and endotoxins); safety studies for viruses and prions; characteri-zation of the final product, lot release test-ing; bioassays and stability studies.

31


Name


FonFax

E-Mail Internet


Chimera Biotec GmbH

Emil-Figge-Str. 76a44227 Dortmund

+49 231 9742-840 +49 231 9742-844 [email protected]

20 2000

Chimera Biotec is the leading provider of ultra sensitive immunoassay development and bioanalytical sample testing. Chimera provides customized services as well as target quantification based on in house assays. Chimera Biotec manufactures and markets ultra sensitive Immuno-assays for pharmacokinetics, pharmacodynam-

ics, immunogenicity assessment, stability testing and biomaker quantification.

Cube Biotech is a provider for protein ex-pression, purification, and crystallization services with a focus on the pharmaceuti-cally relevant class of membrane proteins.

Our services are complemented by affinity tag-based and protein-specific chromatography matrices to offer a unique solution.

Dedicated products for protein purifica-tion and membrane protein crystallization

are manufactured in-house and sold to scientific labs.

Main activities of the CIBUS Biotech GmbH are the development and application of molecular analyses for the examination of processed food, feed, or their single com-ponents as well as other products from pharmacological, cosmetic, paint or paper

industry. Fokus is analysis and product de-velopment to identify e.g. animal species, species of plants, GVO, allergens.

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Cube Biotech GmbH

Alfred-Nobel-Str. 1040789 Monheim

+49 2173 99373-0+49 2173 [email protected]

102012

CIBUS Biotech GmbH

Amselweg 133378 Rheda-Wiedenbrück

+49 5242 40556-0+49 5242 40556-270 [email protected]

72001

32


Name


FonE-Mail

Internet


Name


FonFax

E-Mail Internet


Miltenyi Biotec GmbH

Friedrich-Ebert-Str. 6851429 Bergisch Gladbach

+49 2204 83066-540 +49 2204 8519-7 [email protected] www.miltenyi.tv1,4001989

Lonza Cologne offers products for various uses, such as disinfectants and detergents in hospitals or pool areas, in pesticides against snails, in sports and energy drinks (vitamin B3, L-Carnitine) or in body lotions as emulsifying agents.

Lonza Cologne develops and commer-cializes non-viral gene transfer products for primary cells and hard-to-transfect cell lines. With Lonza’s Nucleofector™ Technol-

ogy, the functionality of different genes can be analyzed in biologically relevant cell types. These results help identify possible new pharmaceuticals and therapies, for example to fight cancer or cardiovascular diseases.

In addition, Cologne is the German distri-bution center for further Lonza businesses such as endotoxin detection, health and hygiene, industrial conservation, material preservation, nutrition and agriculture.

Miltenyi Biotec, is a diversified biotechnology group of companies with a business focus on cellular technologies. M.B. produces and mar-kets state-of-the-art products and technolo-gies for cell separation, cell biology, related molecular biology applications. M.B. focuses on stem cell isolation, immune therapies, tis-sue replacement, with devices and biological

reagent kits for clinical and research use. Miltenyi Biotec also offers in cooperation with nanoPet pharma preclinical imaging agents – the Viscover™ Imaging portfolio. Another asset recently included into the program is lentiviral technology for cell and gene therapy applications. The CliniMACS® Technology al-lows clinicians to separate specific cell types to cure particular diseases. Acquiring OWL biomedical, Inc., Miltenyi Biotec has com-pleted its portfolio by microchip-based cell sorting systems using fully-closed cartridges in an easy-to-use-format, applicable to the research and clinical cell therapy markets.

Lonza Cologne GmbH


+49 221 [email protected]/research

1051998

Name


Fon

E-Mail Internet


PAIA Biotech GmbH offers assays for the rapid quantification of antibodies and proteins based on its proprietary assay technology. It features bead-based im-munoassays with fluorescence detection in specially designed 384-well microplates which drastically simplify the workflow. The

assays are amenable to automation and run on standard plate readers or fluorescence microscopes. PAIA Biotech focuses on products for screening applications with limited sample volume and high throughput requirements, e.g. in early cell line develop-ment.

In addition to off-the-shelf products for IgG and IgG fragments PAIA Biotech GmbH also offers custom assay development. PAIA Biotech GmbH was founded in 2014 and is based at the RTZ in Cologne.

PAIA Biotech GmbH

Gottfried Hagen Str. 60-6251105 Köln

+49 221 16862380

[email protected] 42014

33


Name


FonFax

E-Mail

Internet


Protagen Protein Services (PPS) is a leading contract research organization with an large international customer base in the field of Protein Analytics of biotherapeutics. With more than 17 years of experience in busi-ness, PPS is able to offer a comprehensive, GMP compliant spectrum of state of the art analytical methods, ensure the highest quality for the identification and structural

characterization incl. modification of new biological entities as well as biosimilar prod-ucts. Comprehensive proteome studies and differential protein display techniques are offered in addition for example to support up and downstream process optimization of biotherapeutic production. PPS combines unique expertise in e.g. bioinformatics for protein mass spectrometry with a long track record in protein chemistry and protein analytics. PPS provides you with the full range of services, from drug discovery and development to release testing and regula-tory compliance under ICH Q6B.

Presently the following In Stock products are available: various reporter-gene plas-mids and minicircles, pDG plasmids for the AAV virus production and pEPI /pEpito plasmids with S/MAR elements.

PlasmidFactory’s research and devel-opment as well as its complete service branches are based in Germany. With vari-ous research projects and co-operations, PlasmidFactory is the driving force in the development of gene vectors.

PlasmidFactory is the leading contract manufacturer for plasmid and minicircle DNA. The so-called ‘In Stock products’ are complementing the product portfolio: these plasmids are always in stock and are usually shipped within 48 hours of order.

Name


FonFax

E-Mail Internet


PlasmidFactory GmbH & Co. KG

Meisenstr. 9633607 Bielefeld

+49 521 2997-350 +49 521 2997-355 [email protected]

16 2000

Protagen Protein Services GmbH

Otto-Hahn-Straße 1544227 Dortmund+49 231 9742-6100+49 231 9742-6149contact@ProtagenProteinServices.comwww.ProtagenProteinServices.com701997

BioScienceWE DELIVER CELL SOLUTIONS

tion of basic research into cell therapy. PL BioScience has a broad expertise con-cerning human platelet lysate as a better alternative to fetal bovine serum.

PL BioScience offers diverse plate-let lysates and platelet lysate derived products, e.g. a patent-protected 3D cell culture system.

PL BioScience is a young, ambitious and dynamic life science startup offering a portfolio of novel products and innovative technologies for human cell expansion in research and clinical applications. The company aims to accelerate the transla-

Name


FonFax

E-Mail Internet

Founded (year)

PL BioScience GmbH

Dennewartstraße 25-2752068 Aachen

+49 241 95719-100+49 241 [email protected]

2015

34


Name


FonFax

E-Mail Internet

Founded (year)

Name


FonFax

E-Mail Internet


Sysmex Partec is the collaboration between Partec, a worldwide leading pioneer, devel-oper and manufacturer of flow cytometry systems and Sysmex Corporation, a leading international supplier of in vitro diagnostic products.

Sysmex Partec products are used in a wide range of applications in healthcare,

PS Biotech GmbH is a German developer and producer of polymer based release systems for biotechnological application. Recently the company expanded and moved its headquarter to Herzogenrath. PS Biotech offers unique solutions to en-able strain developers and enzyme produc-ers to optimize their screening processes.

The product portfolio ranges from the well-known Feed Plate®, deepwell microti-

immunology, cell biology, microbiology, biotechnology, agrosciences, plant breed-ing, aquaculture and in pharmaceutical, food and beverage industries.

ter plates releasing glucose for fed-batch emulated high throughput screenings to tailor made solutions.

The products enable obtaining of robust, process-near conclusions during screen-ing, resulting in an optimized scale-up pro-cess of bio production. Synchronization of physiological conditions in screening and production leads to reliable high quality results and thus immensely increases the efficiency within the scope of screening and bio production.

Squarix GmbH biotechnology

Elbestr. 1045768 Marl

+49 2365 915-278 +49 2365 915-254 [email protected]

81992

PS Biotech GmbH

Kaiserstrasse 10052134 Herzogenrath

+49 241 8946441-0+49 241 [email protected]

2013

Name


FonFax

E-Mail Internet


Sysmex Partec GmbH – Branch Office Münster(Headquarter: Am Flugplatz 13, 02828 Görlitz)Otto-Hahn-Str. 3248161 Münster+49 3581 8746-0+49 3581 [email protected]

195 worldwide1967

Squarix GmbH is a privately-held primary manufacturer of high purity Discovery Chemicals and Immunoreagents. Since 1992, Squarix produces a broad product line of compounds that include innovative building blocks, reactive intermediates, natural products and derivatives, screening

compounds for drug discovery industry and reagents for life science applications com-prising antibodies, metabolic intermediates, fluorescent dyes & probes and different af-finity matrices for proteins and cells.

Moreover, Squarix is a custom producer of polyclonal and monoclonal antibodies for biomedical research and offers all type of immunoanalytical services in the field of antibody technology.

35


Taconic Biosciences is a global provider of genetically engineered rodent models and services. Founded in 1952, Taconic helps the biotechnology and pharmaceutical communities acquire, custom generate, breed, precondition, test, and distribute highly relevant research models world-wide. Specialists in Precision Research Models and GEMs Design & Management, Taconic operates three service laborato-

ries and six breeding facilities in the U.S. and Europe and maintains distributor relationships in Asia.

XanTec bioanalytics specializes in biosen-sors and bio-nanocoatings. The company’s core competence are bioinert and bioac-tive nanocoatings for biomedical and bio-analytical applications. Products are SPR biosensor systems, SPR or other biosensor chips and coated slides for protein and DNA microarrays.

vivo Science is a privately held CRO for pre-clinical studies focussing on the immune system. For years now, all regulatory agen-cies such as FDA or EMA very much enforce the testing of immunotoxicity (ICH-S8) and immunogenicity (ICH-S6) of new drug can-didates, especially if derived from biotech-

nology. In addition, vivo Science can also include immunological tests into standard toxicity studies for a medicinal product. vivo Science will provide GLP and GMP compli-ant, validated study protocols and will assist you in setting up a customized test program for your special requirements.

Name


FonFax

E-Mail Internet


Taconic Biosciences GmbH

Neurather Ring 151063 Köln

+49 221 96453-10+49 221 [email protected] www.taconic.com

801952

Name


FonFax

E-Mail Internet


vivo Science GmbH

Fabrikstr. 348599 Gronau

+49 2562 8170-0 +49 2562 8170-19 [email protected]

202001

Name


FonFax

E-Mail Internet


XanTec bioanalytics GmbH

Merowingerplatz 1a40225 Düsseldorf

+49 211 9936-4744 +49 211 9936-4746 [email protected]

101997

36


Xell is an experienced partner for companies in the biotech and pharmaceutical industry providing them with highly-efficient solu-tions in cell culture technology. With years of industry experience, we bring our extensive expertise in high performance media and feed development, and apply our powerful

analytical tools for in-depth characteriza-tion of biological systems and pharmaceuti-cal proteins, guaranteeing optimal solutions for our customers’ bioprocesses.

Based on our proprietary technology, Xell has developed a wide range of customized as well as commercial high-performance culture media, supplements and feeds for specialized production cell lines includ-ing CHO, hybridoma and HEK. Chemically defined and free of animal components, our products meet or exceed all necessary quality standards required for GMP manu-facturing processes.

Name


FonFax

E-Mail Internet


Xell AG

Alte Verler Str. 133689 Bielefeld+49 521 96989-200+49 521 [email protected]

222009 as TeutoCell AG, renamed in 2014

37


38

BIO.NRW

Health and Medicine (including Animal Health)

BIO.NRW health and medicine

39

Name


Fon

E-Mail Internet


Name


Fon

Internet


Name


FonFax

E-Mail Internet

Founded (year)

Adhesys Medical develops fully synthetic, biodegradable surgical adhesives. Based on a polyurethane platform technology two products are currently under devel-opment: The first has been designed for dermal use, to close a great variety of topical wounds faster, more accurately and with fewer complications. The Second is designed for use inside the body: either

Affectis is a pharmaceutical company developing novel proprietary drugs for the treatment of neurodegenerative and neuroinflammatory diseases based on pioneering findings in the field of P2X7 receptors. Affectis will partner or license

as an adhesive, to seal areas of leakage or re-attach tissue, or as a hemostat, to stop bleeding. The company was founded in 2013 in Aachen, Germany. In February 2014, the founders closed a 7-digit seed investment round with S-UBG, KfW and a group of private investors. In April 2014 the team won the Rice Business Plan Compe-tition in Houston, Texas and expanded to the United States after closing a further investment round of $2.7 Mio. with US investors.

its programs at late discovery/early de-velopment stage. The company is located in Dortmund, Germany, and is looking for academic and industrial collaborations for testing its frontrunner compound.

A2M Pharma is a spin-off from Schwarz Pharma with the aim of developing the most promising projects of Schwarz Pharma’s former R&D pipeline that was abandoned for strategic reasons following its merger with UCB.

This portfolio includes projects in neu-rology and pain. A2M Pharma develops these projects until clinical proof of con-

cept which will then be out-licensed or partnered. The current lead projects focus on the treatment of Parkinson’s disease and are supported by the Michael J Fox Foundation. A small molecular modulator of lipid rafts is in preclinical development as an α-synuclein aggregation inhibitor for disease modifying treatment of Par-kinson’s Disease and potential for other protein aggregation disorders. The second lead project focusses on the treatment of dyskinesias and involves a isorotigotine for transdermal delivery.

Adhesys Medical GmbH

Pauwelsstraße 1752074 Aachen

+49 241 41250320

www.adhesys-medical.com

132013

Affectis Pharmaceuticals AG

Otto-Hahn-Str. 1544227 Dortmund

+49 231 97427000+49 231 [email protected]

2006

A2M Pharma GmbH

Alfred-Nobel-Str.1040789 Monheim

+32 484 26 55 06

[email protected]

32009

BIO.NRWhealth and medicine

40

Algiax Pharmaceuticals GmbH is a biotechnol-ogy company that was established in April 2011. It is dedicated to the discovery and development of innovative products in the field of nervous system disease with a strong focus on neuropathic pain. The company’s lead compound AP-325 is currently in clinical development. The comprehensive Phase I program has been finalized (>100 male and fe-

male subjects exposed to AP-325) and shows a good safety and tolerability profile in healthy volunteers after single and multiple dosing. The human PK profile of AP-325 is compatible with once-a-day administration and fast onset of action. A broad patent portfolio covering major commercial markets is solely owned by Algiax. The primary indication is neuropathic pain, the secondary indication is spinal cord injury for which Algiax has an orphan drug des-ignation. Altogether, Algiax is well positioned to take advantage of the market opportunity not only in the field of neuropathic pain but also in other unmet medical diseases.

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


arrows biomedical Deutschland carries out contract research and clinical routine analyses, and also pursues its own R&D projects. The firm’s areas of focus are pri-marily in the fields of molecular oncology and neurodegenerative disease. Its port-folio of molecular analytics includes RNA/DNA. Services like RNA/DNA isolation,

microarrays(GenExpression, Array-CGH, ChIP on chip, DNA-Methylation-Microar-rays), PCR (RT-qPCR) and bioinformatics. In the area of medical diagnostics, the portfolio includes routine analysis (testing for all clini-cal relevant biomarkers and the complete range of blood analysis), flow cytometry (NAVIOS), HPLC analysis, diagnostic micro-arrays, detection of freely circulating tumor cells, and chemosensitive analysis. Further-more, FISH analysis, general microscopy with the Zeiss axio imager M 2 in combina-tion with the MetaSystemsSoftware and Pyro- and Sanger sequencing.

arrows biomedical Deutschland GmbH

Heisenbergstraße 11 48149 Münster+49 251 534064-00+49 251 [email protected]

102005

Algiax Pharmaceuticals GmbH

Max-Planck-Str. 15a40699 Erkrath

+49 211 617851-15+49 211 [email protected] www.algiax.com

62011

AiCuris is a pharmaceutical company fo-cused on discovery, research and develop-ment of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

The most advanced projects in the com-pany’s pipeline are Letermovir (licensed

to MSD), designed to inhibit the viral ter-minase of the human cytomegalovirus, achieved positive results in the Phase 3 study, and Pritelivir, a helicase-primase inhibitor, being developed to treat herpes simplex virus type 1 and type 2 infections. Pritelivir has succesfully completed a Phase 2 trial in genital herpes. Phase 1 development of a topical formulation for the treatment of labial herpes is also completed. Further programs are AIC499, a resistance-breaking gram-negative anti-biotic and AIC649, an immune modulator for the treatment of hepatitis B.

Name


FonFax

E-Mail Internet


AiCuris Anti-infective Cures GmbH

Friedrich-Ebert-Str. 47542117 Wuppertal

+49 202 31763-0 +49 202 31763-1177 [email protected]

55 2006


41

Axiogenesis is the leading provider of com-mercial-grade human induced pluripotent stem cell derived cells, which enable drug development. Validated assays for each cell type have been developed for advanced drug discovery, disease and tissue mod-eling, safety and toxicology. Our innovative and proprietary cells and assays accelerate

and improve drug candidate selection, re-duce time and thus increase drug develop-ment efficiency. The products encompass hiPSC-derived cardiac (Cor.4U®, vCor.4U & FibroCor.4U) and neural cells (Peri.4U, Dopa.4U, Astro.4U & CNS.4U). Products in development include iPSC-derived sensory, cortical and motor neurons as well as ma-tured cardiomyocytes.

As a result of our in-house assay capabil-ity, we can provide expert scientific support in order to facilitate selection and quick implementation of validated assays and technologies.

Name

AddressPostal Code/City

FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Biocheck introduced Polycheck® Platform Technology as a tool for medical differential diagnosis. The multiparameter test device enables a serological quantitative allergy screening on the basis of solid phase Im-muno-Assay-Technology using monoclonal antibody detection; colorcoded devices are presenting different allergen panels.

For autoimmune diagnosis a quantitative screening for disease patterns is new family

member of Polycheck®. Quantitative evalu-ation is performed by picture scanning and calculation by Biocheck Imaging Software.

The assay prodedure can be worked out manually or fully automated including matching with central Laboratory Informa-tion Systems (LIS).

BioCheck GmbH

Vorbergweg 4148159 Münster

+49 251 2150-868 +49 251 2150-870 [email protected]

181999

Baliopharm is a pharmaceutical company firstly offering services for the preclinical and clinical development of biopharmaceu-tical compounds and secondly dedicated to the development of new innovative biophar-maceutical compounds for the treatment of inflammatory diseases such as rheumatoid arthritis, Morbus Crohn and multiple sclero-sis. Our lead product ATROSAB, a human-

ized anti-TNF-receptor antibody, currently in phase I clinical studies, has been proven in head to head comparative, preclinical stud-ies to be more safe and more efficacious as state of the art marketed products.

In addition, Baliopharm s service arm is GLP/GMP certified for analytics needed in preclinical and clinical studies We perform all kind of serum analytics needed for the development of biopharmaceutical com-pounds. We also offer a wide set of cell based potency assays for new biological as well as for biosimilar products.

Baliopharm GmbH

Karl-Heinz-Beckurts-Str. 1352428 Jülich

+49 2461 6210-855 +49 2461 [email protected] 202011

Name

Address

Postal Code/City

FonFax

E-Mail Internet


Axiogenesis AG

Nattermannallee 1Gebäude S2050829 Köln

+49 221 998818-0 +49 221 998818-10 [email protected]

40 2001


42

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenera-tive care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is pub-licly listed on the Frankfurt Stock Exchange (B8F). Biofrontera’s lead product Ameluz® is a prescription drug initially approved and

marketed in Europe and now also approved in the U.S. in combination with the medical lamp BF-RhodoLED® for the treatment of actinic keratosis. Biofrontera is the first Ger-man biotech company to obtain centralized EU and U.S. approval for a medical device/drug it has developed itself. Biofrontera also markets a dermatological range of cosmetics. The Belixos® products contain combinations of active herbal substances, relieve itching and redness and are used for the regenerative care of chronic skin conditions. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this cosmetic line.

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Biofrontera AG

Hemmelrather Weg 20151377 Leverkusen

+49 214 87632-0 +49 214 87632-90 [email protected]

57 1997

CellAct Pharma GmbH is a venture capital backed company focused on the develop-ment of innovative therapeutics for the treatment of cancers with high unmet need.

The small molecule prodrug targeting Topoisomerase, CAP7.1, is currently in

clinical Phase II study for the treatment of refractory biliary tract-, small-cell and non-small cell-lung cancers.

European Medicines Agency has grant-ed orphan drug designation to CAP7.1 for the treatment of refractory biliary tract cancers. The recent interim analysis of the ongoing phase II study in biliary tract cancer indication resulted in favor of CAP7.1 and met the primary objective of disease control including partial response and stable disease with tumor shrinkages.

Carpegen is a provider of high quality mo-lecular diagnostics. The company focuses on developing real-time PCR assays and point-of-care (POC) diagnostics for the diagnosis of specific infections and the detection of genetic biomarkers. Carpegen has developed Carpegen® Perio Diag-nostics, a powerful real-time PCR based

system that sets new standards in micro-biological periodontal diagnostics. A main objective of Carpegen’s research program is to develop and out-license POC/PCR systems for diverse applications in medi-cal and non-medical markets. Two joint R&D projects related to the development of innovative antibiotic resistance diag-nostics and water analytics are currently being pursued with financial support of the state of North Rhine-Westphalia and the German Federal Ministry for Economic Affairs and Energy.

Carpegen GmbH

Mendelstr. 1148149 Münster

+49 251 980-2320 +49 251 980-2321 [email protected]

102001

Name


FonFax

E-Mail Internet


CellAct Pharma GmbH


+49 231 9742-6350 +49 231 9742-6355 [email protected]

72007


43

Name


FonFax

E-Mail Internet

Founded (year)

Name


FonFax

E-Mail Internet


CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP-GT is a regulatory endorsed expression platform for scalable viral vec-tor production. CAP-GT suspension cells grow to high cell densities and show a broad viral propagation spectrum. Gene therapy vectors such as lentivirus (LV), adenovirus

(AV) and adeno-associated virus (AAV) can be produced at industrial scale. CAP-GT enables better scale-up and competitive production costs when compared to adher-ent cell culture systems. CAP-Go enables the production of proteins previously out of reach. The expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor made glyco-sylation of recombinant proteins. The cells highly efficiently produce a broad range of difficult to express glycoproteins and pro-vide authentic human post-translational modifications. Follow CEVEC on LinkedIn.

CEVEC Pharmaceuticals GmbH

Gottfried-Hagen-Str. 60-6251105 Köln

+49 221 46020-800 +49 221 46020-801 [email protected]

2003

Cilian AG is a biotechnology company de-veloping and marketing a novel expression system. The company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of vaccines, monoclonal antibodies and therapeutic enzymes.

Cilian AG

Johann-Krane-Weg 4248149 Münster

+49 251 6203-114 +49 251 6203-116 [email protected] 142001

CIRES is experienced in all kinds of cell culture techniques, ranging from genera-tion of hybridomas, culture of mammalian cells in general and the culture of lines of transgenic cells.

Name

Address

Postal Code/CityFonFax

E-Mail Internet


CIRES cell + immune research services GmbH

BioMedizinZentrum Bochum Universitätsstrasse 136D-44799 Bochum+49 23493696536+49 [email protected]

32001


44

Name


FonFax

E-Mail


Colbourne Pharmaceuticals develops and produces drugs for the treatment of inborn errors in metabolism and offers diagnostic services for molybdenum cofactor defi-ciency and sulphite oxidase deficiency. Colbourne Pharmaceuticals provides ser-vices to Alexion Pharmaceuticals Inc. in the development of cPMP for the treatment of molybdenum cofactor type A deficiency.

ColbournePharmaceuticals GmbH

Viktoriaweg 7 53859 Niederkassel

+49 2208 770505+49 221 [email protected]

62008

First diagnostic test to detect perinatal asphyxia (PA, oxygen deficit during birth) and related braindamage.

PA is very prevalent in childbirth world-wide with 0.5-4% of births affected. Typi-cal outcome brain damage results in e.g. cerebral palsy/spasticism, blindness etc. Therapy is available and reimbursed since 2010, but needs to be started within 6 h

after delivery. No suitable diagnostic ex-ists today. Thus, ca. half of cases are not treated. Still, up to 15 unnecessary treat-ments are applied to cure one patient.

InfanDx develops the first test to be applied immediately after birth. The im-munology like format uses a small blood sample only. Technology origin is metabo-lomics research.

InfanDx seeks partnerships as.– pharma-partnering, („companion diagnostic“, therapy monitoring)– manufacturer of point-of-care device– marketing co-operations

Bridging the gap between academic dis-coveries and pharmaceutical development.

Active in the field of drug discovery, LDC transforms promising early stage projects into marketable assets providing industry with high-quality leads with proof-of-con-cept in animals. These small molecule drug discovery projects are conducted in close

collaboration with world-class academic researchers from LDC’s broad network in-cluding the Max Planck Society, Helmholtz Association and numerous universities. The LDC team consists of experts with solid industry experience in project management as well as Screening, Cellular Biology, Phar-macology and Medicinal Chemistry.

LDC has formed alliances with AstraZen-eca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Qurient und Roche as well as leading academic drug discovery centers worldwide.

Name


FonFax

E-Mail Internet


InfanDx AG

Balthasarstr. 1850670 Köln

+49 221 30089783+49 221 [email protected]

< 102010

Name


FonFax

E-Mail Internet


Lead Discovery Center GmbH


+49 231 9742-7002+49 231 [email protected]

632008


45

LIFE&BRAIN is a development-stage bio-medical enterprise serving as commercial hub of the University of Bonn Medical Center. Integrating a unique set of expertise in Genomics, Transgenics, Cellomics and Neurocognition, we aim at delivering the next generation of products for disease modeling and prediction, compound devel-opment and tissue regeneration.

Products and services include genome and gene expression analysis, industry scale hu-man stem cell-based models of neurologic diseases for compound development as well as electrophysiology services to character-ize small molecules in target engagement, efficacy and potency in human and rodent models.

Matricel GmbH develops and produces innovative medical class III collagen im-plants and biomatrices for applications in medicine and biotechnology. Matricel proprietary technologies are the key to successfully produce biocompatible and biodegradable matrices in a wide range of modifications suitable for the cultivation with human cells in tissue engineering and

regenerative medicine. The products serve different medical fields like ACI-Maix and Cartimaix for tissue engineering of articu-lar cartilage and other orthopedic applica-tions and Remaix as a dental membrane for guided bone regeneration. Matricel s product Optimaix is dedicated for research in 3D cell culture. Matricel has a promising product pipeline in further medical fields like dermal and nerve regeneration with customized scaffolds.

Name


FonFax

E-Mail Internet


Life & Brain GmbH

Sigmund-Freud-Str. 2553127 Bonn

+49 228 6885-100 +49 228 6885-101 [email protected]

40 2002

Name


Fon E-Mail

Internet


Matricel GmbH

Kaiserstr. 10052134 Herzogenrath +49 2407 [email protected]

282001

MetaVì Labs provides drug discovery services for cell migration inhibitors to bio-tech and pharmaceutical companies and research labs worldwide.

MetaVì Labs’ process is based on a 3-D collagen matrix system that recapitulates

the tumor environment to measure live tumor cell migration. This is the only cell migration method that has been clinically validated for in vitro screening of drugs for antimetastatic effects. The company’s patent pending microscopy system au-tomatically tracks thousands of cells as individuals as they migrate freely in 3-D collagen.

Name


Fon Fax

E-Mail Internet

Founded (year)

MetaVì Labs GmbH

Eichenkamp 1046244 Bottrop

+49 2045 4133708+49 2045 4133707 [email protected]

2013


46

Miacom Diagnostics is specialized in de-veloping next-level in vitro diagnostic tests for the identification of pathogens causing acute systemic diseases. Miacom improves critical patient care by providing rapid mo-lecular diagnostic tools designed for routine use to promote more efficient antibiotic therapies and help healthcare organiza-tions reduce costs. Our proprietary Direct Multiplex Imaging (DMI) assays deliver

results in less than 30 minutes directly from patient samples without need of tedious sample preparation or DNA amplification. In addition to the world´s only molecular diagnostic (MDx) test that identifies all rel-evant pneumonia-related bacteria directly from sputum, miacom offers CE & FDA cleared multiplex test for sepsis. Our latest innovation includes a fully automated rapid ID system that allows high-throughput MDx testing of several hundred samples per day. Since 2014 Fosun Diagnostics, the diagnos-tic division of Shanghai Fosun Pharmaceuti-cal, is investor by miacom.

Name


FonFax

E-Mail

Internet


miacom diagnostics GmbH

Merowingerplatz 1a 40225 Düsseldorf

+49 211 3015-5795+49 211 2989-143info@miacom-diagnostics.comwww.miacom-diagnostics.com102006

MLM Medical Labs is a CAP- and DIN EN ISO 15189-accredited, GLP-certified and CLIA-registered central and specialty lab dedicated exclusively to clinical trials. MLM offers the entire portfolio of service elements to support clinical trials:– Development and validation of special analytical methods– MLM Assembly Services® for global supply of sampling kits

– World-wide sample logistics– MLM Safeguard Box® for temperature protected sample shipments– Clinical chemistry, hematology, serology and urinalysis– Biomarker assays including multiplex panels– Long term cryo-storage of samples– Web Access - mlm online®

MLM’s services are offered 365 days a year. We create a reliable partnership with our clients and our core values are:Scientific Excellence / Customized Solu-tions / Personal Accountability

Name


FonFax

E-Mail Internet


MLM Medical Labs GmbH

Dohrweg 6341066 Mönchengladbach

+49 2161 4642102+49 2161 [email protected]

411993

Morphoplant GmbH is a bio-/ medtec company headquartered at the BioMedizin- Zentrum in Bochum and focused on the inte-gration of biotech functionalities into medical devices. Laboratories equipped with state-of-the-art technology for recombinant protein

production, protein chemistry, molecular and cell biology, isotope protein labeling/ monitoring and optical biosensor technol-ogy are available to our experienced and multidisciplinary R&D team. Morphoplant’s proprietary technologies provide our cus-tomers with ultrahydrophilic and osteophilic long-term storable metal implant surfaces and solutions for biocoating of a variety of implant materials with recombinant growth factors (bone/ vascular). Our outstanding expertise in surface functionalization, protein adsorption, kinetics monitoring and animal testing is also available for contract research..

Name


FonFax

E-Mail Internet


Morphoplant GmbH

Universitätsstr. 13644799 Bochum

+49 234 7772870+49 234 [email protected]

142002


47

NEO New Oncology GmbH is a molecular diagnostics company dedicated to the fast, reliable identification and interpretation of all therapy-relevant genomic changes in cancer patient samples.

The proprietary technology platform “NEO” delivers clinically meaningful results from just one small sample, either a tissue paraffin block or blood. Based on advanced

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical devel-opment of innovative therapeutics for treat-ment of severe orphan brain diseases based on its proprietary CNS Drug Delivery Plat-form. The company also intends to partner

diagnostics combined with oncological expertise, “NEO” identifies all available treatment options ranging from standard therapies to clinical studies, enabling clini-cians to fully understand individual cancer profiles and to make informed treatment decisions.

NEO New Oncology is part of Siemens Healthineers.

its drug delivery technology for application to proprietary compounds of pharmaceuti-cal companies to exploit its therapeutic use in the field of CNS indications. Besides that NEUWAY initiated the development of a vac-cine to treat a rare but frequently fatal neuro-logical disease called progressive multifocal leucoencephalopathy (PML). The company is backed with venture capital from renowned investors and a strong board.

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


NEO New Oncology GmbH

Gottfried-Hagen-Str. 2051105 Köln

+49 221 888 238-0+49 221 888 [email protected]

352012

NEUWAY Pharma GmbH

Ludwig-Erhard-Allee 253175 Bonn

+49 228 522798-0+49 228 [email protected]

162014

Nexigen GmbH leverages its extensive R&D experience in peptide therapeutics for the efficient discovery and rational develop-ment of peptide medicines (“NexiTides”) with qualified cellular mechanisms of ac-tion.

Nexigen’s technologies give access to high value drug targets which pose signifi-

cant challenges to conventional discovery approaches. Targets include aberrantly activated intracellular disease pathways in so-called cancer stem cells, for which currently no treatment alternatives exist, but which are main drivers of tumor recur-rence and spread.

Nexigen was founded in 2007 and is headquartered at the BioCampus Cologne, Germany.

Name


FonFax

E-Mail Internet


Nexigen GmbH


+49 221 337772-00+49 221 337772-29 [email protected]

232007


48

PAION AG is a publicly listed specialty phar-maceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based se-dation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and control-lable benzodiazepine sedative/anesthetic

drug candidate. Currently, remimazolam is in active Phase III clinical development for use in procedural sedation in the U.S.

Remimazolam is partnered in the U.S., Canada, China, Russia (CIS), Turkey, the MENA region, and South Korea.

PAION is headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA).

PAION’s vision is to become an acknowl-edged “PAIONeer” in sedation and anesthe-sia. PAION is listed at the Frankfurt Stock Ex-change (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE000A0B65S3).

Name


FonFax

E-Mail Internet


Paion AG

Martinstr. 10-1252062 Aachen

+49 241 4453-152+49 241 4453-523 [email protected]

392000

Pharmedartis (PMA) develops next genera-tion targeted therapies. This platform tech-nology of Human Cytolytic Fusion Proteins (HCFP) has several advantages over well-received ADCs. A binder is recombinantly fused to a payload. This can be proteases,

RNases or kinases. Since the binder can be almost anything making it truly scalable. Human payloads should have much less side-effects. We look for partner interested in out-licensing opportunities for these first-in-class products. We develop CFPs to treat cancer, inflammation, auto-immune and skin diseases. 6 products are in preclini-cal testing. CFPs for clinical testing can be produced in Aachen in proprietary system at a state-of-the-art GMP facility of Fraunhofer Society, of which PMA is a spin-off. As a one-stop-shop we provide full service from gene to biopharmaceutical product.

Name


FonFax

E-Mail Internet


Pharmedartis GmbH

Forckenbeckstr. 652074 Aachen

+49 241 6085132-60 +49 241 6085132-66 [email protected]

52007

Protagen AG improves Personalized Pa-tient Care

Protagen is a diagnostics company that is a clear technology and IP leader in its field. We are focused on the development and commercialization of novel diagnostic tests for the diagnosis, disease stratification and therapy support in autoimmune disease. The Company’s goal is to facilitate thera-

peutic development and improve treatment strategies for autoimmune diseases, the 2nd most important pharma market today, with an initial focus on RA, SLE, SSc and similar disorders.

We are adding a new dimension to the world of diagnostics and personalized therapy by enabling more successful drug development and better treatment strate-gies. Thus, based on our own IVD product sales and our pharma collaborations, Pro-tagen is in position to capture its first mover advantage and claim a market leading posi-tion in this market.

Name


Fon E-Mail

Internet


Protagen AG


+49 231 9742-6300 [email protected]

311997


49

Protectimmun GmbH is a biopharma-ceutical R&D company focussed on new approaches in the prevention and therapy of allergic and chronic inflammatory dis-eases. Our innovative concept for product development is based on the identifica-

tion of natural substances and bacteria with immunomodulatory properties from particular farm environments which are selectively transferred into pharmaceuti-cal applications. Promising candidates which were successfully tested in proof-of-concept animal models of asthma are currently in mid- to late-stage preclinical development.

Name


FonE-Mail

Internet


Protectimmun GmbH

Universitätsstr. 13644799 Bochum

+49 234 [email protected] < 102007

QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecu-lar insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. As-say technologies make these biomolecules

visible and ready for analysis. Bioinformat-ics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecu-lar testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further informa-tion can be found at www.qiagen.com

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


QIAGEN GmbH

Qiagen Str. 140724 Hilden

+49 2103 29-0 +49 2103 29-22000 [email protected]

> 4,600 worldwide1984

SanguiBioTech GmbH

Alfred-Herrhausen-Str. 4458455 Witten

+49 2302 915200+49 2302 [email protected]

61995

SanguiBioTech GmbH engages research and development of pharmaceutical, medi-cal and cosmetic products. Many of their technologies are patented and unique.


50

Name


FonFax

E-Mail Internet


Soft Intelligent Therapeutics (SIT) is a biotech company focused on personalized cancer treatments combining maximum efficacy with minimum side effects. The first product candidate of its targeted gene delivery platform is designed to separately and selectively deliver via two different

SIT - Soft Intelligent Therapeutics Biotech GmbHOtto-Hahn-Str. 1544227 Dortmund

+49 231 97427252+49 231 [email protected]

62010

binding sites two inactive compounds to cancer cells, where they combine to an ac-tive product initiating apoptotic processes. In parallel SIT develops novel intelligent and highly specific liposomal payloads on DNA basis for different diseases such e. g. Hepatitis B.

Sividon Diagnostics is a spin-off from Siemens Healthcare Diagnostics´ former research group in Köln. Its management team represents decades of professional ex-perience in molecular diagnostics. Sividon develops and markets innovative products to improve the individualized selection of therapies in oncology. The company currently focusses on breast cancer, the

first product being EndoPredict®, a breast cancer test identifying those patients who can be cured with an antihormonal treatment and therefore be spared an ag-gressive chemotherapy. It is worldwide the first RNA-based diagnostic test for breast cancer that can be carried out in any well-equipped molecular pathology laboratory. Also, Sividon is a member of the European study group “RESPONSIFY – Genomebased biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer”. Since May 31, 2016 Sividon is part of the Myriad Genetics group.

The Soluventis-platform is based on the most powerful drug delivery system, an entirely new type of Nanocarrier charac-terized by incomparable high efficacy and a very good safety profile. The Soluventis Nanocarrier shields the transported siRNA, microRNA or peptides from blood and im-

mune system contact, and reaches reliable target organs including poorly vascularized tumor tissue. The targeting of metastases is excellent. The frozen Nanocarrier has a long shelf life in ampoules whereas in the organism it is completely eliminated within two days.

Soluventis has a portfolio of oncologic siRNAs which significantly improve tumor reduction and elimination of metastases in xenograft models. In combination with the novel drug delivery system we offer a faster and more effective development of clinical candidates for pharmaceutical companies.

Name


FonFax

E-Mail Internet


Sividon Diagnostics GmbH


+49 221 669561-00+49 221 [email protected]

202010

Name


Fax Fon

E-Mail

Internet

Founded (year)

Soluventis GmbH

Im Lottental 3644801 Bochum

+49 234 32 29125+49 234 32 [email protected]

2009


51

Name


FonE-Mail

Internet


Syntab Therapeutics is committed to the exploration and development of innovative drugs against severe diseases such as can-cer. Syntab’s synthetic antibodies exhibit all desirable properties of conventional antibodies while, at the same time, being significantly smaller chemically accessible molecules. The company strives for the

early out-licensing of product candidates after completion of the preclinical devel-opment. Syntab’s platform technology enables the chemical synthesis of highly effective drugs against severe diseases such as cancer. The flexibility of the technology is based on the application of diverse highly specific binders against specific cell surface proteins.

Furthermore, the technology has the potential to vary the number and specific properties of binders and effectors that activate the immune system for each drug molecule.

Syntab Therapeutics GmbH

St.-Jobser-Straße 5652146 Würselen

+49 171 [email protected]

< 102010

Transimmune AG is developing novel immu-notherapies based on its unique understand-ing of the physiologic processes underlying the activation of antigen presenting cells. This understanding derives from nearly 30 years of research into the mechanism of ac-tion behind Extracorporeal Photopheresis (ECP), arguably the first FDA-approved cellu-lar immunotherapy. ECP is a highly success-

ful immunological treatment used for many years, mainly in cutaneous T cell lymphoma (CTCL), graft versus host disease (GVHD) and organ transplant rejection. Transimmune has created two core technologies; Transim-munization and Transtolerization. These in-volve protocols for manipulating the immune system that have been reduced to practice through our mouse-to-man development platform, generating compelling preclinical proof-of-concept data. These technologies have the potential to significantly enhance current ECP practice as well as drive its ap-plication more broadly into numerous other indications.

TRANSIMMUNE

Name


FonFax

E-Mail Internet

Founded (year)

Transimmune AG

Königsallee 9040212 Düsseldorf

+49 211 64136110+49 211 8693 [email protected]

2012

52

BIO.NRW

Industrial Biotechnology

BIO.NRW industrial biotechnology

53

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

Autodisplay Biotech GmbH is a biotechnol-ogy company commercializing its propri-etary expression platform for the display of heterologous proteins or peptides on the surface of gram negative bacteria. This cell surface display technology provides

numerous benefits to biocatalysis, the func-tionalisation of solid surfaces and screening applications.

With its custom-tailored products and services, Autodisplay Biotech is an ideal partner for leading companies in the chemi-cal, pharmaceutical and biotechnology industries.

BSV BioScience GmbH was founded in Oct. 2007 in Baesweiler, near the historical city of Aachen. Since June 2010, the company manufactures and markets biological phar-maceutical active ingredients for different therapeutic areas.

One of our key strengths is based on the production of fertility hormones, being sup-

plied either as API or finished injectables, in co-operation with an also GMP approved German license manufacturer. Our main products are: – Human Chorionic Gonadotrophin (HCG),– Human Menopausal Gonadotrophin (HMG),– Follicle Stimulating Hormone (FSH),– Urokinase (UK), Streptokinase and Ulinastatin (UTI).BSV BioScience GmbH is focused on differ-ent R&D activities, continuously pursuing improvements in the field of API´s and finished dosage forms.

Autodisplay Biotech GmbH

Merowinger Platz 1a40225 Düsseldorf

+49 211 20951378+49 211 [email protected]

92008

BSV Bioscience GmbH

Max-Planck-Strasse 12 52499 Baesweiler

+49 2401 8047-10+49 2401 [email protected]

182007

bitop AG

Stockumer Str. 2858453 Witten

+49 2302 914-400 +49 2302 914-4010 [email protected] 1993

bitop AG focuses on the development, manufacture and marketing of medical de-vices and high quality active ingredients for cosmetics. The technological base of bitop AG’s business are substances from the class of extremolytes, in particular the compound Ectoin®. Extremolytes are natural protective

molecules that are formed by microorgan-isms and plants. bitop AG produces such extremolytes in an industrial scale in its own facility in Witten according to its proprietary biotechnological production processes. bitop AG has developed Ectoin®-containing medical devices for the symptomatic treatment of cough and cold, allergies, dry mucosa, inflammatory skin diseases and airway diseases. The marketing and sale of these medical devices is performed by licensees from the pharmaceutical industry. Currently, bitop’s medical devices are avail-able in more than 45 countries worldwide.

BIO.NRWindustrial biotechnology

54

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


At Direvo, we focus on the emerging biomass conversion industry. We are developing and marketing biology-based products and processes utilizing safe and sustainable re-sources for a world still dominated by fossil raw materials. Our powerful scientific tools unleash the full value of biomass in current and novel industrial processes. Direvo is committed to deliver the best technologies

The innovative biotechnology company Cysal GmbH was founded as a spin-out of the University of Münster, Germany.

Cysal focuses on the production of novel biomaterials in the area of biopolymers, peptides, amino acids, and dipeptides on an industrial scale at unprecedented low-cost, and also develops application fields

supporting the needs of our customers and partners for sustainable and profitable processes which are urgently required by the developing BioEconomy.

evoxx technologies GmbH, a German In-dustrial Biotechnology Company, is focus-ing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bio-conversion. With its proprietary enzymes and carbohydrate ingredients, evoxx is active in high growth markets addressing consumer needs in the Global Food Health

& Wellness Sector and Consumer Products Markets. Product development is based on the proprietary technology and patent plat-form covering the whole value chain from early enzyme and process development to industrial scale production and product deregulation. evoxx industrial partners and customers benefit from the unique metagenomics libraries, the enzyme and carbohydrate development skills and tech-transfer and production capabilities. evoxx is located on the Creative Campus in Monheim am Rhein and on the Biotech Campus Hermannswerder in Potsdam.

for these biomaterials to serve humans and animals. Cysal’s business strategy aims at out-licensing its technology plat-form to interested companies and/or offering its raw materials for incorpora-tion into consumer products for various markets.

The main target markets are those for energy food additives and sport nutrition, cosmetics and skin care, dental hygiene, clinical nutrition, immunomodulation, impotence and infertility, as well as in the area of animal feed production, especially for aquaculture.

Direvo Industrial Biotechnology GmbH


+49 221 47448-0 +49 221 47448-111 [email protected]

302008

Cysal GmbH

Mendelstraße 1148149 Münster

+49 251 980-2490+49 251 [email protected]

52012

evoxx technologies GmbH

Alfred-Nobel-Str. 1040789 Monheim am Rhein

+49 2173 4099-40+49 2173 [email protected]

402016 (evocatal 2006)


55

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

GEN-IAL GmbH is a specialist labora-tory for DNA based food and feed analyses. GEN-IAL offers services and kits for GMO-, allergene- and animal identity analyses as well as bacteria- and yeast detection and differentiation. We offer training in PCR, contract research, several kits for DNA-extraction, PCR-kits for beer/wine spoilage

bacteria and yeast, pathogenes (Salmo-nella, Listeria, Campylobacter, Legionella), genetically modified organism (GMO), allergenes, plant and animal-identity. The laboratory is accredited (DIN EN ISO/IEC 17025) and official cross checking labora-tory. We are member in the German official working group for method development for GMO detection and quantification. We are listed laboratory for the American NON-GMO- Project.

New: Capturing of microorganism by polymer technology

GEN-IAL GmbH

Heuserweg 13-1553842 Troisdorf

+49 2241 252-2980+49 2241 [email protected]

101998

IMAX Discovery is a research driven company, creating new product innovation through the generation and development of novel and natural flavour compounds for the food and beverage industry. Using our strong technol-ogy platforms and expertise around taste re-ceptors and natural products IMAX Discovery generates proprietary product pipelines of

natural product based novel taste modula-tors. IMAX discovery is a 50:50 joint venture company between Axxam SpA in Milano, Italy, and IMD Natural Solutions GmbH in Dortmund, Germany.

IMAX Discovery GmbH


+49 231 97427-402+49 231 97427-401 [email protected]

2010

IMD Natural Solutions (“INS”) aims to develop and commercialize groundbreak-ing ingredients – with a special focus on preserving and anti-microbial agents – de-rived from “all” natural sources. The main target markets are in the Food & Beverage as well as the Personal Care industries. Two product candidates are in advanced

development: AM-1 represents a new (patent pending) all natural antimicrobial preserving agent well suited to support product specifications for food, beverage and personal care applications. AX-1 is targeting oil preservation via its strong antioxidant profile. INS follows a dual busi-ness model; besides the development of preserving agents INS provides Natural Product Service as one-stop service part-ner for all needs associated with Natural Product research, development, produc-tion or supply.

Name


FonFax

E-Mail

Internet


IMD Natural Solutions GmbH

Otto-Hahn-Str. 1544227 Dortmund+49 231 9742-7400+49 231 9742-7401info@imd-natural-solutions.comwww.imd-natural-solutions.com102012

BIO.NRWindustrial biotechnology

56

Name


FonFax

E-Mail Internet


multiBIND develops innovative decontami-nation, disinfection and hygiene solutions for molecular biology, healthcare and agricul-ture. Core technologies are patent-pending systems to generate new disinfection and decontamination agents for consumer markets, hospitals, laboratories and agro-

chemistry. bioDECONT® and bioCLEANTM are the only agents that in addition to the effective killing of microorganisms also accomplish safe and complete decon-tamination of genetic material (DNA/RNA). Besides the highly efficient antimicrobial action and decontamination properties they are nontoxic for humans, non-corrosive and free of organic solvents or other hazardous chemicals. multiBIND pursues a partnering strategy for new applications and markets from suitable industry sectors. multiBIND offers and holds multiple licenses for prod-ucts and applications.

m2p-labs GmbH

Arnold-Sommerfeld-Ring 252499 Baesweiler

+49 2401 805-330+49 2401 [email protected]

312005

m2p-labs is a supplier of microbioreactors for the Life-Science industry. The company focuses on microreaction and automated solutions for screening and bioprocess de-velopment. The product portfolio comprises the BioLector®, the RoboLector® (automa-

tion) and the disposable FlowerPlate® (MTP) which provide an intelligent micro fermenta-tion platform. This technology empowers the biotechnology, chemical and pharmaceutical industry to increase the number and the information content of microbial experi-ments (aerobic, microaerophilic and strict anaerobic). Experiments can be conducted with high efficiency and good quality at low costs. Automated fermentation of the whole bioprocess is possible with the RoboLector®, a combination of the BioLector® system with a standard liquid handling robot. m2p-labs | The Microbioreactor Company

Name


FonFax

E-Mail Internet


multiBIND biotec GmbH

Gottfried-Hagen-Str. 60-6251105 Köln

+49 221 2780-211+49 221 [email protected]

32005

Senzyme GmbH develops and produces technical enzymes and other micro-biological products, all of which is well grounded in the company’s substantial experience in solid-state fermentation us-ing filamentous fungi. Currently, the focus

is on the development of intelligent mix-tures of hydrolases, to be used in a most efficient degradation of plant material, e.g. in the course of methane production from biomass.

Name


FonFax

E-Mail Internet


Senzyme GmbH

Gierlichsstr. 653840 Troisdorf

+49 2241 9715-2000+49 2241 [email protected]

302000


57

Name


Fon E-Mail

Internet

Founded (year)

SeSaM-Biotech GmbH

Forckenbeckstraße 5052074 Aachen


2008

For companies using enzymes in their processes or as additives in their products, SeSaM-Biotech is the right partner to boost the enzyme’s performance. With a combined approach of patented mutagenesis technolo-gies and rational design by computational

modelling and simulations, SeSaM-Biotech tunes enzyme properties like activity, ther-mal resilience, protease resistance, solvent/pH stability, and substrate/product inhibi-tion. The track record includes proteases, monooxygenases, lipases, cellulases, amyl-ases, phytases, esterases, glucose oxidases, pectinases, isomerases, laccases, and xyla-nases being applied in the biotechnological sectors pharma, chemistry, cosmetics, flavors, nutrients, feed, laundry, food/bever-ages, biofuel, textiles and paper. All protein evolution projects are provided as a service with attractive IP ownership agreements.

W42 GmbH is your partner for enzyme production and process development. We offer: High performance heterologous protein production in Pichia sp. Wide range of different strains and promoters – best choice for your project. Methanol dependent and Methanol independent high yield protein production. Complete processes are offered including: strain

development – fermentation – DSP – enzyme immobilisation. Since 2005 W42 GmbH has carried out many successful projects for industrial partners in Europe and P.R. China. Several improved strains are running on industrial scale for produc-tion of technical enzymes.

Furthermore W42 is working on rational strain improvement of microorganisms for the optimisation of industrial production of natural compunds (e.g. antibiotics).

Name


FonE-Mail

Internet


W42 Industrial Biotechnology GmbH

Otto-Hahn-Straße 1544227 Dortmund


32005

58

BIO.NRW

Agrobiotechnology

BIO.NRW agrobiotechnology

59

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

AgroProtect GmbH

Forckenbeckstraße 652074 Aachen

+49 2451 9148783+49 2451 [email protected]

2010

Deutsche Saatveredelung AG

Weissenburger Straße 559557 Lippstadt

+49 2941 296-0+49 2941 [email protected]

6001923

Deutsche Saatveredelung AG is an inter-national plant breeding company with headquarters in Germany. The main focus is on research and development in breed-ing and seed production for different crop plant species.

Our major products include rapeseed, wheat, barley, corn/maize, pasture and

It is estimated that plant pathogens are re-sponsible of world-wide losses in the range of billions of Euros per year. Therefore, there is a strong need to provide effective, broad range and environmentally friendly approaches to ensure protection of plants

turf grasses, and different intercrop spe-cies. Breeding is run on nine breeding stations in Europe and two in Canada. We are dedicated to our purpose: Innovation for your growth. Seed of new varieties is produced and processed mostly in Europe and sold world-wide.

In the framework of several coopera-tions in breeding, production, marketing and sales DSV is partner of several com-petitive enterprises on the national and international level.

from pathogens. We developed a patented platform based on antibody fusions which ensures plant protection from fungal and bacterial infections. This alternative ap-proach for controlling plant pathogens and parasites aims at minimising the costs for cultivation of crops thereby reducing the toxic effects of pesticides and toxins for human beings.

AgroProtect GmbH licences its propri-etary technology and offers the genera-tion of pathogen resistant plants as well as access to novel resistant cultivars of several crops.

MykoMax GmbH

Flieth 3942327 Wuppertal

+49 202 3171-320+49 202 [email protected]

31999

The company MykoMax was created in October 1999 in the legal form of a limited company (GmbH). The enterprise article of the society is the study, development and production of biotechnology products on the basis of fungi. The company offers al-

ready within the mycological product range several self-developed mycorrhiza-inoculi.

On short and medium-term the company MykoMax GmbH would development new drugs from medicinal effective mush-rooms for the pharmaceutical use. There-by the company uses a self-developed method for the extraction of the active ingredients in the mushrooms.

BIO.NRWagrobiotechnology

60

Name


FonFax

E-Mail

Internet


Name


FonFax

E-Mail Internet


Saaten-Union Biotec offers services and contract research in the field of plant breeding (wheat, rapeseed, barley, triti-cale, oat, hybrid rye, durum wheat, fodder and amenity grasses). The development

BIOTEC

of new varieties of cereals, rapeseed and other crops is strongly build upon innovation. Application of tissue culture technologies (doubled haploids, embryo rescue) and molecular marker applica-tions are routinely used in a wide range of crops and for a significant number of breeding traits.

Phytowelt operates industrial plant bio-technology. It is a leading provider for the identification and expression of genes en-coding plant enzymes with new activities for industrial fermentation processes with a main activity on fatty acids, terpenoids and plant P450 enzymes. Additionally

Phytowelt offers solutions in plant breed-ing to improve plants by protoplast fusion and double haploid production Phytowelt’s improvement of biomass production by this accelerated breeding processes is the basis for the biorefinery concept to be realized in the coming years. The USP of a poplar breeding collection combined with the unique fermentation process for terpenes in E.coli, especially carotinoids is one of the success factors for Phytowelt.The raspberry flavour, R-Alpha-Ionone will be one of the first products fermentatively produced.

Phytowelt GreenTechnologies GmbH

Kölsumer Weg 3341334 Nettetal

+49 2162 77859+49 2162 89215 [email protected]

30 1998

Saaten-Union Biotec GmbH

Hovedisser Str. 9433818 Leopoldshöhe

+49 5208 9597-10+49 5208 9597-195 [email protected] 1984

BIO.NRW agrobiotechnology

61

62

BIO.NRW

Bioinformatics

BIO.NRW bioinformatics

63

IIT BioTech - Institut für Innovationstransfer an der Universität Bielefeld GmbH

Universitätsstr. 25 University of Bielefeld33615 Bielefeld+49 521 100-775+49 521 [email protected]

Name

Address

Postal Code/CityFonFax

E-Mail Internet


Ridom GmbH

Mendelstr. 1148149 Münster

+49 251 490931-50+49 251 [email protected] www.ridom.de

42003

The Ridom GmbH (Münster, Germany) was founded January 2003. The company devel-ops software for DNA re-sequencing analysis for physicians and epidemiologists on routine basis. The company has in the meantime by its software products a well-recognized name in the field of sequence based microbial typing;

e.g., every European National Health System Authority (e.g., RKI, RIVM, HPA, Serum Stat-ens) has bought in the last 10 years and is using since then at least one software product from Ridom. Ridom has pioneered typing ef-forts with a software tool for Staphylococcus aureus. The company has developed and maintains the worldwide largest sequence-based microbial typing database (Ridom SpaServer). The SPA typing software Ridom StaphType is currently used by approximately 400 users in 36 different countries world-wide. The new Ridom SeqSphere+ software provides a bacterial typing solution for any bacteria, any study type, any lab.

Name


FonFax

E-Mail Internet


The Institut für Innovationstransfer GB Biotech (IIT Biotech) offers integrated genomic services. Since some years the main provided service is the ’next genera-tion sequencing’.

The high-throughput techniques per-formed by Illumina HiSeq and MiSeq or by IonTorrent PGM can be offered combined with a powerful lab & bioinformatic pipeline providing full service tasks like genomic as-sembly, gap closure and annotation.

Furthermore we offer individual solutions for the bioinformatic evaluation of project data. This includes construction of draft-genomics, storage/care of genome projects, analysis in resequencing and metagenomics and development/customization of analysis-software.

64

BIO.NRW

Other Biotechnologically Active Companies

BIO.NRW other

65

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet


Name


Fon

Internet

Employees

Bayer AG

Kaiser-Wilhelm-Allee51368 Leverkusen

+49 214-30-1

www.bayer.com

117,000

Evonik Industries AG

Rellinghauser Str. 1-11 45128 Essen

+49 201 177 01+49 201 177 [email protected]

33,000 2007

German Seed Alliance GmbH

Erdmund-Rumpler-Straße 651149 Köln

+49 2203 9888-20+49 2203 [email protected]

452008

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its prod-ucts and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to cre-ate value through innovation, growth and high earning power. Bayer is committed to

the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion.

These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

For more information, go to www.bayer.com

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its inno-

vative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,000 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.4 billion.

Evonik innovates and serves the bioec-onomy markets. Products are i. a. Biolys®, DYNACOLL® Terra, DYNAPOL® Terra, RESOMER®, ThreAMINO®, TrypAMINO®, and VESTAMID® Terra.

German Seed Alliance GmbH is an alliance of four leading German plant breeding companies in international agriculture: Deutsche Saatveredelung, Norddeutsche Pflanzenzucht, Nordsaat Saatzucht and SaKa. The company and its shareholders are internationally experienced enterprises in the field of plant research and development, breeding, seed production and distribution.

The main focus is on oilseed rape, potatoes, corn, sunflower, grasses, peas and cere-als (especially wheat, barley, rye, oat and triticale). German Seed Alliance coordinates all research programs of the group and is partner of the national and international scientific community in plant research and biotechnology. New varieties are developed and high quality seeds are produced for dif-ferent climate regions. In sales the first focus is on Russian Federation, with innovative solutions and wide range of seed products combined with professional service and individual consultancy.

BIO.NRWother

66

Name


FonFax

E-Mail Internet


Name


Fon E-Mail

Internet


Name


FonFax

Internet

Employees

Founded (year)

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepre-neurial specialist delivering true benefits to patients. By sustainably investing in research and development above the indus-trial average, we are committing to innova-

tion in order to treat unmet medical needs and bring valueadding products to markets. Grünenthal is a fully integrated research & development company with a long track re-cord of bringing innovative pain treatments and state-of-theart technologies to patients. Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,400 employees are working for the Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of € 1.2 bn.

Grünenthal GmbH

Zieglerstr. 652099 Aachen

+49 241 569-0 [email protected]

5,4001946

Janssen-Cilag is a research-based pharma-ceutical company that develops and mar-kets pharmaceutical products and services. The Janssen Pharmaceutical Companies of Johnson & Johnson with worldwide 40,000 employees develop innovative medicines for the treatment of severe chronic conditions

and evaluates programmes that improve therapies beyond the mere administration of drugs. Janssen is dedicated to address-ing and solving the most important unmet medical needs of our time, including on-cology, immunology, neuroscience and infectious diseases. Driven by our commit-ment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and trans-parency. More information can be found at www.janssen-emea.com and www.janssen-deutschland.de

Janssen-Cilag GmbH

Johnson & Johnson Platz 141470 Neuss

+49 2137 9550+49 2137 955599www.janssen-deutschland.de

800 (Germany),40,000 (worldwide)1959

Henkel operates worldwide with leading brands and technologies in three business areas: Laundry & Home Care, Beauty Care and Adhesive Technologies.

Founded in 1876, Henkel holds glob-ally leading market positions both in the consumer and industrial businesses with wellknown brands such as Persil, Schwarzkopf and Loctite.

Henkel employs about 49,000 people and reported sales of 18,089 million euros and adjusted operating profit of 2,923 million euros in fiscal 2015.

Henkel’s preferred shares are listed in the German stock index DAX.

Henkel AG & Co. KGaA

Henkelstr. 6740191 Düsseldorf

+49 211 7979630+49 211 7982245www.henkel.com

49,0001876

BIO.NRW other

67

Name


FonFax

E-Mail Internet


Name


Fon E-Mail

Internet


Name


FonFax

E-Mail Internet

Founded (year)

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality.

Monsanto remains focused on enabling both small-holder and large-scale farm-ers to produce more from their land while

conserving more of our world’s natural resources such as water and energy.

Monsanto Agrar Deutschland GmbH

Vogelsanger Weg 9140470 Düsseldorf

+49 211 3675-0+49 211 [email protected]

2000

Syngenta is one of the world’s leading companies in agribusiness with more than 26,000 employees in over 90 countries. We are dedicated to our purpose: Bringing plant potential to life.

Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve

health and quality of life. At the core of our business is innovation, particularly in research and development, combining chemical and biological expertise.

We harness our knowledge of agricul-ture and our understanding of growers to develop integrated offers which will drive land productivity in a sustainable way.

Syngenta Seeds GmbH

Zum Knipkenbach 20 32107 Bad Salzuflen

+49-5222 [email protected]

1502000

Since over 70 years, Pharma Waldhof GmbH, located in Düsseldorf/Germany, is active in the unique world of Nucleic Acid Biochemis-try. The last milestones in our long company history were in 2014 and 2016 the award of the label “Innovative through Research” by the “Stifterverband für die deutsche Wis-senschaft” and in 2015 the acknowledge-ment by the “Deutscher Bildungspreis” as

an “Excellence company for Training and Talent Management”. Development of new products using cutting-edge technology enables us to apply our high standards and quality values into innovative, powerful and well-accepted products designed for existing and new markets. Our success is based on our highly skilled people and pursuit for de-livering quality value added products serving the worldwide market in various segments like Pharma APIs and Intermediates; Cos-metics; Nutrition and Diagnostics. Pharma Waldhof belongs to the multi-national Aceto Group/USA.

Pharma Waldhof GmbH

Hansaallee 15940549 Düsseldorf

+49 211 52602-43+49 211 [email protected]

131974

BIO.NRWother

68

Name


FonFax

E-Mail Internet


Name


FonFax

E-Mail Internet

Founded (year)

Name


FonFax

E-Mail Internet


W. von Borries-Eckendorf is a medium-sized family-owned company, founded in 1849 by Wilhelm von Borries (1805-1890), a promi-nent farmer and talented plant breeder. Starting with the “Eckendorfer” fodder beet,

WvB is nowadays well known for strong breeding programs in oilseed rape, barley and high yielding wheat varieties.

The company based in Lippe is founding member of the Rapool Ring GmbH and the Saaten-Union Biotec GmbH.

Along with other breeding companies, Eckendorf is significantly involved in one of the largest distributors in the German sector of seed. The Saaten-Union GmbH.

ECK

EN

D

OR F E R

SO

RT

E

N

Taros, a privately owned CRO / CMO has been serving the needs of pharmaceutical, chemical and biotech companies since 1999. More than 10.000 synthesis, research and process chemistry projects have suc-cessfully been delivered to the global cus-tomer base. Taros’ scientists combine more than 140 years industrial organic chemistry

experience and over 60 years of active drug discovery experience. They have expertise in major therapeutic areas and in all small molecule target classes.

Taros have developed TarosGate®, a unique software suite putting cost, time and chemistry information at a Project Leader’s finger tips - 24h/7 from anywhere in the world.

TarosGate® is a major cornerstone of the 200 Mio. Euro European Lead Factory drug discovery platform.

Taros Chemicals GmbH & Co. KG

Emil-Figge-Str. 76 a44227 Dortmund

+49 231 9742-7211+49 231 [email protected]

551999

UCB is a global biopharmaceutical com-pany focusing on severe diseases in two therapeutic areas – CNS and immunol-ogy. UCB also has a selective presence in primary care.

UCB is connecting science in new ways, notably chemistry and biology, so that they can leverage the potential of these two disciplines, as well as illuminate the

biological pathways involved in severe diseases. The complexities of severe diseases are beyond the expertise and resources of a single organisation. De-veloping and commercialising innovative therapies is often the result of strong partnerships. That is why we value part-nering with leading academic, biotech and pharma companies to bring new solutions for patients. There is no such thing as an “average patient”. We are seeking to embed the real needs of specific patient populations in our science and innovation process.

UCB Pharma GmbHUCB Biosciences GmbH

Alfred-Nobel-Str. 1040789 Monheim

+49 2173 4848-48+49 2173 4848-41 [email protected]; www.ucb.de

1928 (Belgium)

W. von Borries-Eckendorf GmbH & Co. KGPflanzenzuchtbetrieb

Hovedisser Str. 92 33818 Leopoldshöhe+49 5208 9125-30+49 5208 9125-49 [email protected]

401849

BIO.NRW other

bio.nrw.de company database

Innovative biotech companies in North Rhine-Westphalia. BIO.NRW offers free of charge a well-or-ganized and comprehensive database of life science and biotech companies resident in North Rhine-Westphalia. The database currently includes 450 company profiles, contact details and a summary of products, services and technologies and is updated frequently several times per year.

phone: +49 211 38 54 69-9200 • E-Mail: [email protected]

70

BIO.NRW

North Rhine-Westphalia is situated at Eu-rope’s geographic and economic center. It is the largest of Germany’s 16 federal states, and the number one exporter. If classified as an independent exporting nation, NRW would rank 19th in the world, on a par with the Netherlands.

North Rhine-Westphalia’s state govern-ment has established a number of technology clusters to systematically improve NRW’s strengths and talents in established industries and up-and-coming fields like biotechnology.

North Rhine-Westphalia’s biotechnol-ogy cluster BIO.NRW is a central catalyst for the sustainable development of the state’s biotech sector. It activates cooperation between business, research, investors and policy-makers. The cluster also promotes the strengths and achievements of biotechnology in the state.

To support young as well as already estab-lished biotech companies, BIO.NRW offers the following core competencies:– Individual matchmaking for collabora-

tions and partners– Overview on all up-to-date R&D activi-

ties in industry and academia– Profound knowledge on financing pos-

sibilities– International promotion and marketing

for NRW as biotech location– Direct contacts to decision makers

Our services include

Technology TransferTech transfer support is a key contribution from BIO.NRW. We organize events, work-ing platforms and meetings to promote the

BIO.NRW Cluster Biotechnology North Rhine-Westphalia

biotech developments in NRW please visit www.bio.nrw.de.

Further drivers in the field are dynamic local biotechnology initiatives and networks:

Bioanalytik-Münster www.bioanalytik-muenster.de

BioColognewww.biocologne.de

bio.dortmundwww.wirtschaftsfoerderung-dortmund.de

BioIndustrywww.bioindustry.de

BioRiverwww.bioriver.de

Bio-Tech-Region OWLwww.bio-owl.de

LifeScienceNet Düsseldorfwww.lifescience-dus.de

MedLife (Aachen)www.medlife-ev.de

Cluster Industrial Biotechnologywww.CLIB2021.com

dialogue between all stakeholders in the field of biotechnology and to encourage cooperation.

Biotech Business & SciencesBIO.NRW compiles comprehensive and current online databases of the academic institutions and companies active in the life sciences in NRW. Free to access and easy-to-use, these resources are valuable tools for identifying prospective business partners. More information on www.bio.nrw.de

Fairs, Exhibitions and ConferencesCompanies and academic institutions can generate awareness of their activities locally, nationally and internationally by being a part of the BIO.NRW common stands on fairs, exhibitions and conferences. BIO.NRW also organizes a series of workshops and sympo-sia, called BIO.NRW.academy.

Support of Young ProfessionalsBIO.NRW takes a special interest in support-ing young professionals in biotechnology. For example, we organize conventions where graduates meet representatives from indus-try and academic science. The ‘Business Angel Network – BIO.NRW’ helps financing and funding biotech start-ups. In addition, a forum that brings together investment institutions, private investors and business angels and developers provides informa-tion about the current NRW biotech scene. These meetings are a valuable opportunity for start-up companies to receive coaching and financing.

To learn more about the Cluster BIO.NRW and to stay informed about the latest

71

BIO.NRW

München

Dresden

Potsdam

Hannover

j

Düsseldorf

Schwerin

Magdeburg

Kiel

Erfurt

Stuttgart

Saarbrücken

Frankfurt

Mainz

Berlin

Bremen

Hamburg

Poland

AustriaSwitzerland

France

Netherland

Czech Republic

Denmark

Luxembourg

Belgium

72

Glossary

Organisation for Economic Co-operation and Development (OECD)

The OECD is a unique forum where the gov-ernments of 30 democracies work together to address the economic, social and environ-mental challenges of globalisation.

The OECD Biotechnology Statistics, which brings together the latest available economic and activity data on biotechnology and in-novation, is collected by OECD member and non-member countries.

The report builds on the extensive work of the OECD and national experts to im-prove the comparability of biotechnology statistics.

www.oecd.org

OECD Definitions

Biotechnology company

… is defined as a application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the produc-tion of knowledge, goods and services.

Dedicated biotechnology companies

… are defined as biotechnology active firms whose predominant activities involve the application of biotechnology techniques to produce goods or services and/or the per-formance of biotechnology R&D.

Other biotechnologically active companies

… firms that apply biotechnology techniques for the purpose of implementing new or sig-nificantly improved products or processes.

This definition excludes end users that innovate simply by using biotechnol-ogy products as intermediate inputs (for instance, detergent manufacturers that change a formulation to include enzymes produced by other firms via biotechnology techniques).

Business Areas of Activity

– Health/Medicine (including animal health)

Development of therapeutics and/or diag-nostics for the field of human medicine, drug delivery, human tissue replacement.

– Agri/Agrobiotechnology Biotech focussed on genetically modified plants, animals or microorganisms, as well as non-genetically modified plants grown using biotechnological procedures for use in agriculture or forestry.

– Industrial biotechnologyBiotechnological products and processes for the handling of waste or sewage, for chemical synthesis, for the extraction of raw materials and energy, etc.

– Non-specific applicationEquipment or reagents based on biotechno-logical principles for research or provision of services in this field (“ancillary industry”).

Source: biotechnologie.de

BIO.NRW

Contact BIO.NRW

Dr. Christoph BlockHead of office BIO.NRWMerowingerplatz 140225 Düsseldorf, GermanyFon +49 211 385469-9202Fax +49 211 [email protected]

Sources, Literature, Links

[1] www.nrwinvest.com/en/nrw-at-a-glance/location-factors-nrw/business-location-germany-nrw/

[2] World Bank 07/2016[3] Analysis by BIO.NRW and BIO Deutschland

e.V.[4] Estimating the biotech sector’s contribution

to the US economy; Robert Carlson; Nature Biotechnology 34, 247–255 (2016)

[5] OECD Biotechnology Statistics 2009, B. van Beuzekom and A. Arundel

[6] NRW PCT Biotech Patent Analysis by BIO.NRW[7] statista[8] Compared to surveys from Biocom 14/15[9] http://data.worldbank.org/indicator/

GB.XPD.RSDV.GD.ZS [10] statista - Leading German dedicated bio-

technology companies by number of em-ployees worldwide in 2015

[11] www.biotechgate.com; Venture Valuation, Zurich, CH

[12] Based on own survey in comparison to: Im Schatten von Leuchttürmen, Potenziale besser ausschöpfen, Deutscher Biotechnol-ogie-Report 2016, Ernst & Young GmbH

[13] Biotech-Report “Medizinische Biotechnolo-gie in Deutschland 2016” von vfa bio und BCG; www.vfa-bio.de

[14] www.leitmarktagentur.nrw/leitmarktwett-bewerbe/lifesciences/runde1

73

BIO.NRW

BIO Clustermanagement NRW GmbHMerowingerplatz 140225 Düsseldorf, Germany

Welcome to ourprivate equity community

Apply for funding from business angels and investors!

Register and upload your 3-minute biotech/life science company video!

Get the attention of a large investors community and get invited to a face-to-face meeting!

What are you waiting for?

www.startups4.eu

Apply Now

phone: +49 (0) 211 942 150 49mail: [email protected]: www.bioclustermanagement.de

74

BIO.NRW

BIO.NRWMerowingerplatz 1 40225 Duesseldorf GermanyFon + 49 (0) 2 11 385 469 - 9200Fax + 49 (0) 2 11 385 469 - [email protected]

Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia 40221 Duesseldorf www.innovation.nrw.de

www.exzellenz.nrw.de ‘Excellence NRW’ stands for the cluster strat-egy in North Rhine-Westphalia, an innovative location for business. The state government there wants to improve on its strengths, and systematically strive for excellence in NRW. The goal of the cluster policy is to create an environment that is friendly to innovation, strengthens the competitive edge of the businesses there, and stimulates growth and employment. To find out more about NRW’s cluster strategy and the 16 clusters in the state, just visit: www.exzellenz.nrw.de

BIO.NRWMerowingerplatz 1 40225 Düsseldorf, GermanyFon +49 211 385469-9200Fax +49 211 [email protected]

Ministry of Innovation, Science and Research of the German State of North Rhine-Westphalia 40221 Düsseldorf www.innovation.nrw.de

ww

w.b

io.n

rw.d

e

Company

Directory

Spot on Biotechnology Business 2015/2016

Online

Company

Database

www.bio.nrw.de

Online

Company

Database

www.bio.nrw.de

Spot on Biotechnology Business 2016/2017 · Spot on Biotechnology Business 2016/2017 e ny e de....

Documents

Transcript of Spot on Biotechnology Business 2016/2017 · Spot on Biotechnology Business 2016/2017 e ny e de....